<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1450" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1450/" /><meta name="ncbi_pagename" content="Amyotrophic Lateral Sclerosis Overview - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Amyotrophic Lateral Sclerosis Overview - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Amyotrophic Lateral Sclerosis Overview" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/10/03" /><meta name="citation_author" content="Nailah Siddique" /><meta name="citation_author" content="Teepu Siddique" /><meta name="citation_pmid" content="20301623" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1450/" /><meta name="citation_keywords" content="Lou Gehrig Disease" /><meta name="citation_keywords" content="ALS" /><meta name="citation_keywords" content="Lou Gehrig Disease" /><meta name="citation_keywords" content="ALS2-Related Disorders" /><meta name="citation_keywords" content="SETX-Related Amyotrophic Lateral Sclerosis" /><meta name="citation_keywords" content="SOD1-Related Amyotrophic Lateral Sclerosis" /><meta name="citation_keywords" content="TARDBP-Related Amyotrophic Lateral Sclerosis" /><meta name="citation_keywords" content="VAPB-Related Amyotrophic Lateral Sclerosis" /><meta name="citation_keywords" content="ANG-Related Amyotrophic Lateral Sclerosis" /><meta name="citation_keywords" content="FUS-Related Amyotrophic Lateral Sclerosis" /><meta name="citation_keywords" content="FIG4-Related Amyotrophic Lateral Sclerosis" /><meta name="citation_keywords" content="VCP-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia" /><meta name="citation_keywords" content="OPTN-Related Amyotrophic Lateral Sclerosis" /><meta name="citation_keywords" content="C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia" /><meta name="citation_keywords" content="UBQLN2-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia" /><meta name="citation_keywords" content="PFN1-Related Amyotrophic Lateral Sclerosis" /><meta name="citation_keywords" content="Alsin" /><meta name="citation_keywords" content="Angiogenin" /><meta name="citation_keywords" content="Annexin A11" /><meta name="citation_keywords" content="Charged multivesicular body protein 2b" /><meta name="citation_keywords" content="Cilia- and flagella-associated protein 410" /><meta name="citation_keywords" content="Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrial" /><meta name="citation_keywords" content="D-amino-acid oxidase" /><meta name="citation_keywords" content="Dynactin subunit 1" /><meta name="citation_keywords" content="Guanine nucleotide exchange C9orf72" /><meta name="citation_keywords" content="Heterogeneous nuclear ribonucleoprotein A1" /><meta name="citation_keywords" content="Matrin-3" /><meta name="citation_keywords" content="Myelin-associated oligodendrocyte basic protein" /><meta name="citation_keywords" content="Optineurin" /><meta name="citation_keywords" content="Polyphosphoinositide phosphatase" /><meta name="citation_keywords" content="Probable helicase senataxin" /><meta name="citation_keywords" content="Profilin-1" /><meta name="citation_keywords" content="Protein unc-13 homolog A" /><meta name="citation_keywords" content="Receptor tyrosine-protein kinase erbB-4" /><meta name="citation_keywords" content="RNA-binding protein FUS" /><meta name="citation_keywords" content="Sec1 family domain-containing protein 1" /><meta name="citation_keywords" content="Sequestosome-1" /><meta name="citation_keywords" content="Serine/threonine-protein kinase Nek1" /><meta name="citation_keywords" content="Serine/threonine-protein kinase TBK1" /><meta name="citation_keywords" content="Spatacsin" /><meta name="citation_keywords" content="Superoxide dismutase [Cu-Zn]" /><meta name="citation_keywords" content="TAR DNA-binding protein 43" /><meta name="citation_keywords" content="TATA-binding protein-associated factor 2N" /><meta name="citation_keywords" content="Transitional endoplasmic reticulum ATPase" /><meta name="citation_keywords" content="Tubulin alpha-4A chain" /><meta name="citation_keywords" content="Ubiquilin-2" /><meta name="citation_keywords" content="Vesicle-associated membrane protein-associated protein B/C" /><meta name="citation_keywords" content="ALS2" /><meta name="citation_keywords" content="ANG" /><meta name="citation_keywords" content="ANXA11" /><meta name="citation_keywords" content="C9orf72" /><meta name="citation_keywords" content="CFAP410" /><meta name="citation_keywords" content="CHCHD10" /><meta name="citation_keywords" content="CHMP2B" /><meta name="citation_keywords" content="DAO" /><meta name="citation_keywords" content="DCTN1" /><meta name="citation_keywords" content="ERBB4" /><meta name="citation_keywords" content="FIG4" /><meta name="citation_keywords" content="FUS" /><meta name="citation_keywords" content="HNRNPA1" /><meta name="citation_keywords" content="MATR3" /><meta name="citation_keywords" content="MOBP" /><meta name="citation_keywords" content="NEK1" /><meta name="citation_keywords" content="OPTN" /><meta name="citation_keywords" content="PFN1" /><meta name="citation_keywords" content="SCFD1" /><meta name="citation_keywords" content="SETX" /><meta name="citation_keywords" content="SOD1" /><meta name="citation_keywords" content="SPG11" /><meta name="citation_keywords" content="SQSTM1" /><meta name="citation_keywords" content="TAF15" /><meta name="citation_keywords" content="TARDBP" /><meta name="citation_keywords" content="TBK1" /><meta name="citation_keywords" content="TUBA4A" /><meta name="citation_keywords" content="UBQLN2" /><meta name="citation_keywords" content="UNC13A" /><meta name="citation_keywords" content="VAPB" /><meta name="citation_keywords" content="VCP" /><meta name="citation_keywords" content="Amyotrophic Lateral Sclerosis" /><meta name="citation_keywords" content="Overview" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Amyotrophic Lateral Sclerosis Overview" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Nailah Siddique" /><meta name="DC.Contributor" content="Teepu Siddique" /><meta name="DC.Date" content="2019/10/03" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1450/" /><meta name="description" content="The purpose of this overview is to increase the awareness of clinicians regarding genetic causes of amyotrophic lateral sclerosis (ALS) and related genetic counseling issues." /><meta name="og:title" content="Amyotrophic Lateral Sclerosis Overview" /><meta name="og:type" content="book" /><meta name="og:description" content="The purpose of this overview is to increase the awareness of clinicians regarding genetic causes of amyotrophic lateral sclerosis (ALS) and related genetic counseling issues." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1450/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/als-overview/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1450/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE89B1E7E0403A510000000008F503EF.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1450_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1450_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/amish-mcph/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/acpp/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1450_"><span class="title" itemprop="name">Amyotrophic Lateral Sclerosis Overview</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Lou Gehrig Disease</div><p class="contrib-group"><span itemprop="author">Nailah Siddique</span>, RN, MSN and <span itemprop="author">Teepu Siddique</span>, MD, DSc (hc).</p><a data-jig="ncbitoggler" href="#__NBK1450_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1450_ai__"><div class="contrib half_rhythm"><span itemprop="author">Nailah Siddique</span>, RN, MSN<div class="affiliation small">Division of Neuromuscular Medicine<br />Davee Department of Neurology and Clinical Neurosciences<br />Northwestern University Feinberg School of Medicine<br />Chicago, Illinois<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.nretsewhtron@euqiddisn" class="oemail">ude.nretsewhtron@euqiddisn</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Teepu Siddique</span>, MD, DSc (hc)<div class="affiliation small">Division of Neuromuscular Medicine<br />Davee Department of Neurology and Clinical Neurosciences;<br />Department of Cell and Molecular Biology<br />Northwestern University Feinberg School of Medicine<br />Chicago, Illinois<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.nretsewhtron@euqiddis-t" class="oemail">ude.nretsewhtron@euqiddis-t</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 23, 2001</span>; Last Update: <span itemprop="dateModified">October 3, 2019</span>.</p><p><em>Estimated reading time: 32 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="als-overview.Summary" itemprop="description"><h2 id="_als-overview_Summary_">Summary</h2><p>The purpose of this overview is to increase the awareness of clinicians regarding genetic causes of amyotrophic lateral sclerosis (ALS) and related <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> issues.</p><p>The following are the goals of this overview:</p><div><h4 class="inline">Goal 1.</h4><p>Describe the <a href="#als-overview._escape__1_Clinical_Charact">clinical characteristics</a> of ALS.</p></div><div><h4 class="inline">Goal 2.</h4><p>Review <a href="#als-overview._escape__2_Genetic_Causes_o">genetic causes</a> of ALS.</p></div><div><h4 class="inline">Goal 3.</h4><p>Provide an <a href="#als-overview._escape__3_Evaluation_Strat">evaluation strategy</a> to identify the genetic cause of ALS in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> (when possible).</p></div><div><h4 class="inline">Goal 4.</h4><p>Inform <a href="#als-overview._escape__4_Genetic_Counseli">genetic counseling</a> of family members of an individual with ALS.</p></div><div><h4 class="inline">Goal 5.</h4><p>Provide a high-level view of <a href="#als-overview._escape__5_Management_of_AL">management</a> of ALS.</p></div></div><div id="als-overview._escape__1_Clinical_Charact"><h2 id="_als-overview__escape__1_Clinical_Charact_">1. Clinical Characteristics of ALS</h2><div id="als-overview.Clinical_Manifestations_of"><h3>Clinical Manifestations of ALS</h3><p>Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disease involving both the brain and spinal cord. While it has traditionally been perceived to be a syndrome primarily affecting motor neurons, there is increasing recognition that additional areas within the frontal and temporal lobes are involved to varying degrees in a subset of patients. In addition, other systems outside the nervous system may be involved, such as bone (Paget disease of the bone) and muscle (inclusion body myopathy). The location and extent of the degeneration determines the clinical picture, which by definition includes motor decline, and may include cognitive and/or behavioral symptoms as well. There is wide variability in presentation, progression, and survival [<a class="bk_pop" href="#als-overview.REF.hardiman.2017.17071">Hardiman et al 2017</a>].</p><div id="als-overview.Motor_Involvement"><h4>Motor Involvement</h4><p>Motor symptoms occur as the result of degeneration of both upper and lower motor neurons. Upper motor neurons (UMNs), located in the motor cortex of the frontal lobe, send their axons through the great corticofugal tracts to the brain stem (corticobulbar neurons) and the spinal cord (corticospinal neurons) to influence patterned activity of the lower motor neurons (LMNs). Additional UMN influences on the LMN are carried over descending pathways of the brain stem. UMN signs in ALS include hyperreflexia, extensor plantar response, and increased muscle tone. LMNs, located in the brain stem and spinal cord, innervate striated muscle. LMN signs in ALS include weakness, muscle wasting (atrophy), hyporeflexia, muscle cramps, and fasciculations.</p><p>Early manifestations may vary, with <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals most often presenting with either asymmetric focal weakness of the extremities (stumbling or poor handgrip) or bulbar findings (dysarthria, dysphagia). Other findings may include muscle fasciculations, muscle cramps, and lability of affect, but not necessarily mood. A diagnostic feature of ALS, typically not seen in other neurodegenerative disorders, is the presence of hyperreflexia in segmental regions of muscle atrophy, unaccompanied by sensory disturbance.</p><p>At presentation, limb involvement occurs more often than bulbar involvement. Various subtypes of ALS have been identified:</p><ul><li class="half_rhythm"><div>"Progressive bulbar palsy," which presents with speech disturbance and swallowing difficulties</div></li><li class="half_rhythm"><div>Limb-onset ALS</div></li><li class="half_rhythm"><div>Progressive muscular atrophy, where lower motor neurons are primarily involved</div></li><li class="half_rhythm"><div>UMN-predominant ALS</div></li></ul></div><div id="als-overview.Neuropsychological_Involvem"><h4>Neuropsychological Involvement</h4><p>Recent studies of both the genetics and neuropathology of ALS have reinforced the understanding that while the syndrome of ALS by definition involves the motor system, wider frontotemporal degeneration may give rise to at least some degree of cognitive and behavioral dysfunction. White matter structural abnormalities in the frontal and temporal lobes of individuals with ALS who do not demonstrate evidence of cognitive decline have also been identified [<a class="bk_pop" href="#als-overview.REF.abrahams.2005.321">Abrahams et al 2005</a>].</p><p>It has been reported that upwards of 45% of individuals with ALS have some degree of cognitive impairment at some time during their illness [<a class="bk_pop" href="#als-overview.REF.raaphorst.2012.493">Raaphorst et al 2012</a>, <a class="bk_pop" href="#als-overview.REF.beeldman.2016.611">Beeldman et al 2016</a>]. Several neuropsychological domains may be affected. The most common deficits are in executive function (demonstrated by difficulties with emotional and impulse control, flexible thinking, self-monitoring, planning and prioritizing, organization, task initiation, and working memory), verbal fluency, and social cognition (demonstrated by difficulties interpreting the emotional states of others and lack of insight in social situations) [<a class="bk_pop" href="#als-overview.REF.beeldman.2016.611">Beeldman et al 2016</a>].</p><p>Symptoms can range from mild to severe.</p><p>On the severe end of the spectrum, frontotemporal dementia (FTD), particularly the behavioral variant of FTD (bvFTD), marked by severe apathy and progressive declines in socially appropriate behavior, judgment, and self-control, as well as personality change, has been reported to range from 5% to 27% in various series [<a class="bk_pop" href="#als-overview.REF.raaphorst.2012.493">Raaphorst et al 2012</a>]. However, a more recent Italian population-based study suggests the incidence may be closer to 10% [<a class="bk_pop" href="#als-overview.REF.montuschi.2015.168">Montuschi et al 2015</a>], or perhaps close to 5%. Additionally, individuals with ALS with FTD (ALS/FTD) experience more language disturbance (difficulty with grammar and sentence and syntactic comprehension) than is generally associated with bvFTD alone [<a class="bk_pop" href="#als-overview.REF.saxon.2017.675">Saxon et al 2017</a>]. Generally, visuospatial dysfunction is not present.</p><p>ALS/FTD tends to be associated with bulbar-onset ALS, with its incidence reported to be 39%-61% [<a class="bk_pop" href="#als-overview.REF.raaphorst.2012.493">Raaphorst et al 2012</a>]. Either motor or neuropsychological manifestations may appear first in individuals with ALS/FTD. When features of ALS appear first, FTD becomes apparent on average 16 months later, whereas when features of FTD appear first, ALS becomes apparent on average 18 months later [<a class="bk_pop" href="#als-overview.REF.raaphorst.2012.493">Raaphorst et al 2012</a>].</p><p>Individuals with ALS with milder neuropsychological manifestations may exhibit executive dysfunction and deficits in verbal and nonverbal fluency and concept formation early in the disease course, particularly in the presence of bulbar onset of disease [<a class="bk_pop" href="#als-overview.REF.schreiber.2005.772">Schreiber et al 2005</a>]. These more subtle manifestations may well be missed with routine mental status examination. Formal neuropsychological testing can be helpful in identifying subtle alterations, particularly alterations that may be masked by socially favorable traits such as empathy and optimism. These favorable traits, well known to specialists dealing with ALS, may lead to considerable bonding between the health care team and persons with ALS. Affected individuals are also generally well liked by their families, as social connections are retained and their "positive" attitudes are appreciated.</p></div><div id="als-overview.Course"><h4>Course</h4><p>Regardless of the initial manifestations, atrophy and weakness eventually spread to other muscles in additional regions. Oculomotor neurons are generally resistant to degeneration in ALS but may be affected in individuals with a long disease course, particularly when life is extended by ventilatory support. Once all muscles of communication and expression are paralyzed, the individual is "locked in." In some instances, eye movements may remain intact, allowing communication by way of special devices.</p><p>Death most often results from failure of the respiratory muscles, but other causes, such as pulmonary embolism or cardiac arrhythmias, may supervene.</p><p>Overall, ALS is a highly heterogeneous disorder with widely varying ages of onset, ranging from childhood to the ninth decade. Males are more commonly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> than females in a ratio of about 1.3/1. The mean age of onset in males is approximately 55 years, while females are most commonly affected in their mid-60s. Individuals with genetic forms of ALS tend to have an earlier onset of symptoms. Disease duration is similarly variable, ranging from months to several decades. About half of affected individuals expire within five years of symptom onset. Individuals younger than age 55 years at onset tend to survive longer, regardless of gender [<a class="bk_pop" href="#als-overview.REF.magnus.2002.709">Magnus et al 2002</a>].</p><p>Traditionally, ALS has been discussed in light of the individual's family history, with "<a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS" indicating that two or more close relatives are known to be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with ALS and "<a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> ALS" indicating that no other relatives are known to have ALS. As genetic research in ALS has evolved and the clinical use of genetic testing has increased, this terminology is shifting. In this <i>GeneReview</i>, "genetic ALS" refers to ALS caused by a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a known ALS <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, regardless of family history. "ALS of unknown cause" will refer to ALS in which a pathogenic variant in a known ALS gene has <i>not</i> been identified, <i>regardless</i> of family history.</p><p>It is estimated that about 10%-15% of individuals with ALS have genetic ALS. Some of the genetic forms of ALS may confer particular clinical characteristics, although intra- and <a class="def" href="/books/n/gene/glossary/def-item/interfamilial-variability/">interfamilial variability</a> of age at onset and disease progression is common (see <a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater" rid-ob="figobalsoverviewTgeneticamyotrophiclater">Table 2a</a> and <a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later_1/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater1" rid-ob="figobalsoverviewTgeneticamyotrophiclater1">Table 2b</a>).</p></div></div><div id="als-overview.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis of ALS</h3><p>The diagnosis of ALS requires characteristic clinical features and specific findings on electrodiagnostic testing, as well as exclusion of other health conditions with related manifestations (see <a href="#als-overview.Differential_Diagnosis_of_A">Differential Diagnosis of ALS</a>). The most commonly employed consensus criteria for its diagnosis are the revised Escorial criteria [<a class="bk_pop" href="#als-overview.REF.brooks.2000.293">Brooks et al 2000</a>]. Additional evaluation of electromyographic information as outlined in the Awaji criteria [<a class="bk_pop" href="#als-overview.REF.de_carvalho.2008.497">de Carvalho et al 2008</a>] may establish the diagnosis more quickly than the Escorial criteria alone. Due to variability in clinical presentation and the lack of biomarkers for the disease, it is not uncommon for several months to a year to pass from symptom onset to a firm diagnosis.</p><div id="als-overview.Clinical_Features"><h4>Clinical Features</h4><p>The <b>Escorial criteria (revised)</b> [<a class="bk_pop" href="#als-overview.REF.brooks.2000.293">Brooks et al 2000</a>] were developed to standardize diagnosis of ALS for research studies, while the <b>Awaji criteria</b> incorporate changes that allow earlier diagnosis. Although not all clinicians employ such stringent criteria, these are increasingly used in everyday practice. They include:</p><ul><li class="half_rhythm"><div>The <b>presence</b> of all of the following:</div><ul><li class="half_rhythm"><div>Evidence of lower motor neuron (LMN) degeneration by clinical, electrophysiologic, or neuropathologic examination</div></li><li class="half_rhythm"><div>Evidence of upper motor neuron (UMN) degeneration by clinical examination</div></li><li class="half_rhythm"><div>Progressive spread of symptoms or signs within a region or to other regions, as determined by history or examination</div></li></ul></li><li class="half_rhythm"><div>Together with the <b>absence</b> of both of the following:</div><ul><li class="half_rhythm"><div>Electrophysiologic or pathologic evidence of other disease processes that could explain the signs of LMN and/or UMN degeneration</div></li><li class="half_rhythm"><div>Neuroimaging evidence of other disease processes that could explain the observed clinical and electrophysiologic signs</div></li></ul></li></ul><p>Clinical evidence of UMN and LMN signs in the four regions of the central nervous system (i.e., brain stem, cervical, thoracic, or lumbosacral spinal cord) can be obtained through detailed or focused history and physical and neurologic examinations.</p><p>The clinical diagnosis of ALS, without pathologic confirmation, may be categorized into various levels of certainty by clinical and laboratory assessment based on the revised Escorial criteria [<a class="bk_pop" href="#als-overview.REF.brooks.2000.293">Brooks et al 2000</a>]:</p><ul><li class="half_rhythm"><div><b>Clinically definite ALS.</b> The presence of UMN and LMN signs in three regions</div></li><li class="half_rhythm"><div><b>Clinically definite <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a>, laboratory-supported ALS.</b> Progressive upper and/or lower motor neuron signs in at least a single region (in the absence of another cause for the abnormal neurologic signs) in an individual with an identified ALS-causing variant</div></li><li class="half_rhythm"><div><b>Clinically probable ALS.</b> The presence of UMN signs and LMN signs in at least two regions with some UMN signs necessarily rostral to the LMN signs</div></li><li class="half_rhythm"><div><b>Clinically probable, laboratory-supported ALS.</b> Clinical signs of UMN and LMN dysfunction in only one region, or UMN signs alone present in one region, and LMN signs defined by electromyographic (EMG) criteria present in at least two limbs in an individual with an identified ALS-causing variant</div></li><li class="half_rhythm"><div><b>Clinically possible ALS.</b> Clinical signs of UMN and LMN dysfunction found together in only one region, UMN signs found alone in two or more regions, or LMN signs found rostral to UMN signs when the diagnosis of clinically probable, laboratory-supported ALS cannot be established</div></li><li class="half_rhythm"><div><b>Clinically suspected ALS.</b> A pure LMN syndrome</div></li></ul></div><div id="als-overview.Electrodiagnostic_Testing"><h4>Electrodiagnostic Testing</h4><p>Electromyography (EMG) can demonstrate electrophysiologic evidence of LMN involvement in clinically affected or clinically uninvolved regions. The Awaji consensus criteria [<a class="bk_pop" href="#als-overview.REF.de_carvalho.2008.497">de Carvalho et al 2008</a>] amend the Escorial criteria to allow electrophysiologic evidence of chronic neurogenic change in a given limb to be taken as equivalent to clinical evidence of involvement of that limb. Additionally, within the category of suspected ALS, the criteria propose equating fasciculation potentials with denervation. These changes make the Escorial category "clinical probable, laboratory-supported ALS" unnecessary.</p></div><div id="als-overview.Establishing_Frontotemporal"><h4>Establishing Frontotemporal Spectrum Involvement</h4><p>Level 1 of the <b>revised Strong consensus ALS-frontotemporal spectrum disorder diagnostic criteria</b> (2017) provides a framework appropriate for use in the clinical setting for establishing the extent of frontotemporal involvement in ALS. The Strong criteria propose a three-"axis" strategy for evaluation:</p><ul><li class="half_rhythm"><div>Axis 1. Defining the motor neuron disease variant using the Escorial criteria while incorporating the Awaji recommendations and testing for genetic variants known to cause ALS</div></li><li class="half_rhythm"><div>Axis 2. Defining neuropsychological deficits:</div><dl class="temp-labeled-list"><dt>a.</dt><dd><p class="no_top_margin">ALS with behavioral impairment (ALSbi): presence of apathy with or without behavior change OR presence of two non-overlapping supportive diagnostic features from the Raskovsky criteria [2011], which include disinhibition, inertia, loss of sympathy/empathy, perseverative/compulsive behaviors, hyperorality, and dysexecutive neuropsychological profile.</p></dd><dt>b.</dt><dd><p class="no_top_margin">ALS with cognitive impairment (ALSci): evidence of either executive dysfunction (including social cognition) or language dysfunction, or a combination of both. Executive impairment is defined as impaired verbal frequency (letter) OR impairment in two other non-overlapping measures of executive function, which may include social cognition.</p></dd><dt>c.</dt><dd><p class="no_top_margin">ALS with both behavioral and cognitive impairment (ALScbi): both criteria for ALSci and ALSbi are met.</p></dd><dt>d.</dt><dd><p class="no_top_margin">ALS/FTD: evidence of progressive deterioration of behavior and/or cognition by observation or history AND the presence of three behavioral/cognitive symptoms from Raskovsky criteria (2011) OR the presence of at least two behavioral/cognitive symptoms together with loss of insight and/or psychotic symptoms OR the presence of language impairment meeting criteria for semantic dementia / semantic variant of primary progressive aphasia (PPA) or nonfluent PPA.</p></dd></dl></li><li class="half_rhythm"><div>Axis 3. Identification of any additional nonmotor manifestations, such as extrapyramidal signs, cerebellar or autonomic dysfunction, sensory impairment, and/or eye movement abnormalities</div></li></ul></div><div id="als-overview.Neuropsychological_Evaluati"><h4>Neuropsychological Evaluation</h4><p>The gold standard for neuropsychological evaluation is a neuropsychological examination administered by a neuropsychologist that includes an interview and a series of standardized tests that assess intelligence, executive function (including planning, abstraction, and conceptualization), attention, memory, language, perception, sensorimotor functions, motivation, mood state and emotion, quality of life, and personality style. Since this testing requires several hours and a specialized practitioner, it is generally not readily available in most clinical settings. Therefore, several tools have been developed that are appropriate for screening and brief assessments. The revised Strong criteria recommend use of the following:</p><ul><li class="half_rhythm"><div><b>Edinburgh Cognitive and Behavioral ALS Screen (ECALS).</b> Designed for use by non-neuropsychology health professionals, the ECALS assesses a range of functions typically affected in ALS, such as fluency, executive functions, and language functions, in addition to functions that are not typically altered in ALS, including nonspecific memory and visuospatial functions. It includes a separate semistructured interview with an informant/caregiver that addresses the five key behavioral domains altered in FTD. The cognitive components of the test were designed to accommodate persons with verbal and motor disability [<a class="bk_pop" href="#als-overview.REF.abrahams.2014.9">Abrahams et al 2014</a>]. ECALS has been validated against standard neuropsychological testing, and good <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> and specificity (85% each) have been demonstrated [<a class="bk_pop" href="#als-overview.REF.niven.2015.172">Niven et al 2015</a>]. It is available at <a href="https://ecas.psy.ed.ac.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ecas.psy.ed.ac.uk</a>.</div></li><li class="half_rhythm"><div><b>ALS Cognitive Behavioral Screen (ALS-CBS).</b> The ALS-CBS can be administered by any clinic staff member in about five minutes. Since responses can be written, spoken, or indicated by mouthing or eye movements or with assistive technology, it is useful in patients with marked motor impairment. Scores at or below ten on the cognitive section, which addresses attention, concentration, working memory, fluency, and tracking, are reliably associated (100%) with diagnosis of FTD in persons with ALS/FTD diagnosed by comprehensive neuropsychological testing. The behavioral component is a 15-item Likert scale questionnaire completed by an informant/caregiver which addresses behavioral change since symptom onset. Scores &#x02264;36 suggest behavioral impairment, while scores &#x02264;32 suggest FTD [<a class="bk_pop" href="#als-overview.REF.woolley.2010.303">Woolley et al 2010</a>]. The ALS-CBS is available at <a href="https://cp.neurology.org/content/neurclinpract/suppl/2017/10/11/CPJ.0000000000000397.DC1/Appendix_E-1.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">cp.neurology.org</a>.</div></li></ul></div><div id="als-overview.Pathologic_Criteria"><h4>Pathologic Criteria</h4><p>It is helpful to remember that both ALS and FTD are clinical diagnoses. Pathologic verification is required for either diagnosis to be considered definitive. See <a class="bk_pop" href="#als-overview.REF.bigio.2013.314">Bigio [2013]</a> for a discussion of pathologic criteria.</p></div></div><div id="als-overview.Differential_Diagnosis_of_A"><h3>Differential Diagnosis of ALS</h3><p>Depending on the clinical presentation, several other hereditary and acquired conditions may need to be considered before establishing the diagnosis of ALS (<a class="figpopup" href="/books/NBK1450/table/als-overview.T.singlegene_disorders_of_i/?report=objectonly" target="object" rid-figpopup="figalsoverviewTsinglegenedisordersofi" rid-ob="figobalsoverviewTsinglegenedisordersofi">Table 1</a>). See <a class="bk_pop" href="#als-overview.REF.goutman.2017.1332">Goutman [2017]</a> for a diagnostic algorithm. For specific genetic disorders see <a class="figpopup" href="/books/NBK1450/table/als-overview.T.singlegene_disorders_of_i/?report=objectonly" target="object" rid-figpopup="figalsoverviewTsinglegenedisordersofi" rid-ob="figobalsoverviewTsinglegenedisordersofi">Table 1</a>.</p><div id="als-overview.T.singlegene_disorders_of_i" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Single-Gene Disorders of Interest in the Differential Diagnosis of ALS</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1450/table/als-overview.T.singlegene_disorders_of_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__als-overview.T.singlegene_disorders_of_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_2" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_3" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Clinical Features of Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_4" id="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Overlapping w/ALS</th><th headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_4" id="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_2_2" scope="col" rowspan="1" colspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Distinguishing from ALS</th></tr></thead><tbody><tr><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>AR</i></td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/kennedy/">Spinal and bulbar muscular atrophy</a></td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_4 hd_h_als-overview.T.singlegene_disorders_of_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LMN signs: weakness, atrophy, fasciculations</td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_4 hd_h_als-overview.T.singlegene_disorders_of_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>No UMN involvement</div></li><li class="half_rhythm"><div>Proximal weakness</div></li><li class="half_rhythm"><div>Sensory involvement</div></li><li class="half_rhythm"><div>Slowly progressive</div></li><li class="half_rhythm"><div>Males only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a></div></li><li class="half_rhythm"><div>May have gynecomastia, testicular atrophy, &#x00026; &#x02193; fertility</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BSCL2</i></td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/spg17/"><i>BSCL2</i>-related neurologic disorders</a>&#x000a0;<sup>2</sup></td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_4 hd_h_als-overview.T.singlegene_disorders_of_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">UMN &#x00026; LMN involvement</td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_4 hd_h_als-overview.T.singlegene_disorders_of_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Slowly progressive</div></li><li class="half_rhythm"><div>Abnormal vibration sense</div></li><li class="half_rhythm"><div><i>Pes cavus</i></div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GBE1</i></td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/apbd/">Adult polyglucosan body disease</a></td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_4 hd_h_als-overview.T.singlegene_disorders_of_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">UMN &#x00026; LMN involvement, cognitive impairment</td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_4 hd_h_als-overview.T.singlegene_disorders_of_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Slowly progressive</div></li><li class="half_rhythm"><div>Distal sensory loss</div></li><li class="half_rhythm"><div>Early neurogenic bladder</div></li><li class="half_rhythm"><div>Cerebellar dysfunction</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HEXA</i></td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/tay-sachs/">Chronic and adult-onset hexosaminidase A deficiency</a></td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_4 hd_h_als-overview.T.singlegene_disorders_of_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LMN &#x0003e; UMN involvement, possible cognitive impairment</td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_4 hd_h_als-overview.T.singlegene_disorders_of_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Spinocerebellar degeneration</div></li><li class="half_rhythm"><div>Dystonia</div></li><li class="half_rhythm"><div>Slowly progressive</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SMN1</i></td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/sma/">Spinal muscular atrophy IV</a></td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_4 hd_h_als-overview.T.singlegene_disorders_of_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proximal &#x0003e; distal muscle weakness &#x00026; atrophy</td><td headers="hd_h_als-overview.T.singlegene_disorders_of_i_1_1_1_4 hd_h_als-overview.T.singlegene_disorders_of_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Onset typically in 2nd-3rd decade</div></li><li class="half_rhythm"><div>No UMN involvement</div></li><li class="half_rhythm"><div>Symmetric weakness &#x00026; atrophy</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; LMN = lower motor neuron; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; UMN = upper motor neuron; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="als-overview.TF.1.1"><p class="no_margin">Genes are in alphabetic order.</p></div></dd><dt>2. </dt><dd><div id="als-overview.TF.1.2"><p class="no_margin">The spectrum of <i>BSCL2</i>-related neurologic disorders includes Silver syndrome and variants of Charcot-Marie-Tooth neuropathy type 2, distal hereditary motor neuropathy (dHMN) type V, and spastic paraplegia 17.</p></div></dd></dl></div></div></div><p><b>Other genetic disorders</b> include the following:</p><ul><li class="half_rhythm"><div>The distal hereditary motor neuropathies, or Charcot-Marie-Tooth disease (CMT). See <a href="/books/n/gene/cmt/">Charcot-Marie-Tooth Hereditary Neuropathy Overview</a>.</div></li><li class="half_rhythm"><div>The hereditary spastic paraplegias, or HSP. See <a href="/books/n/gene/hsp/">Hereditary Spastic Paraplegia Overview</a>.</div></li><li class="half_rhythm"><div>Primary lateral sclerosis (PLS) refers to the presence of slowly progressive, uncomplicated signs of upper motor neuron disease in persons in whom all other known causes of spasticity have been eliminated. Controversy exists as to whether PLS is a separate disorder or a subtype of ALS. Upper motor neuron-predominant ALS has little, often late, involvement of LMNs. Adult-onset PLS is not known to be a genetic disorder, although at least a portion of juvenile-onset PLS is an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> genetic condition that may present as a progressive ascending paralysis first noted in infancy [<a class="bk_pop" href="#als-overview.REF.strong.2005.8">Strong &#x00026; Gordon 2005</a>]. Pathogenic variants in at least one <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (<i>ALS2</i>) are associated with both ALS and PLS (see <a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later_1/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater1" rid-ob="figobalsoverviewTgeneticamyotrophiclater1">Table 2b</a>).</div></li></ul><p><b>Acquired disorders</b> include cervical spine disease, brain stem or spinal cord tumors, thyroid disorders, lead poisoning, vitamin B<sub>12</sub> deficiency, multiple sclerosis, paraneoplastic syndrome with occult cancer, motor neuropathies, myasthenia gravis, myasthenic syndrome, and inclusion body myositis.</p><p>If there are UMN signs in the legs and LMN signs in the arms, cervical spondylosis with cervical stenosis should be considered as well. However, cervical spondylosis is common, so it may be identified concomitantly in individuals who have ALS.</p><p><b>Environmental exposures</b> have long been suspected of contributing to development of ALS, particularly in the context of specific genetic backgrounds. Numerous studies have implicated a large number of environmental factors, ranging from place of residence, to work exposures, to athletic endeavors. Most of these studies have been small due to the relative rarity of available subjects and may suffer from methodologic limitations as well. In 2016 Belbasis et al examined 16 unique meta-analyses of ALS and various risk factors. They conclude that only one factor, chronic occupational exposure to lead, convincingly demonstrated a robust association with ALS. Less convincingly associated were exposures to farming and heavy metals other than lead, intake of &#x003b2;-carotene, and head injury. Weak associations were identified with n-3 fatty acid intake, extremely low-frequency electromagnetic field exposure, pesticide exposure, and uric acid level. Rural living, serum lipid levels, statin use, and smoking were not found to be associated with ALS [<a class="bk_pop" href="#als-overview.REF.belbasis.2016.96">Belbasis et al [2016]</a>.</p><p>An excess of ALS cases has been reported in younger Gulf War veterans, particularly in the decade following the war [<a class="bk_pop" href="#als-overview.REF.haley.2003.750">Haley 2003</a>, <a class="bk_pop" href="#als-overview.REF.horner.2003.742">Horner et al 2003</a>]. Environmental exposures, including desert dust that contained cyanobacteria and &#x003b2;-N-methylamino-L-alanine (BMAA), have been posited to be the explanation [<a class="bk_pop" href="#als-overview.REF.cox.2009.109">Cox et al 2009</a>].</p></div></div><div id="als-overview._escape__2_Genetic_Causes_o"><h2 id="_als-overview__escape__2_Genetic_Causes_o_">2. Genetic Causes of ALS</h2><p>For the purposes of this <i>GeneReview</i>, individuals with "genetic ALS" are defined as those having a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a known ALS <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, regardless of family history, while individuals with "ALS of unknown cause" are those who do not have a pathogenic variant in a known ALS gene, regardless of family history (see Clinical Manifestations, <a href="#als-overview.Course">Course</a>). <i>GeneReviews</i> does not use the term "<a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a>" to refer to an individual with no known family history of a disorder; rather, the term "<a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case" refers to a single occurrence of a disorder in a family.</p><p>It is estimated that 10% of individuals with ALS have at least one other family member <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with ALS. Although the frequency of known genetic causes reported in such families ranges widely in various series, it is safe to say that the ALS genes that have been identified account for at least half of ALS that occurs in families with a history of more than one affected relative. Thirty genes implicated with varying degrees of certainty are presented below, with the four most robust and common genes presented in order of prevalence (<a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater" rid-ob="figobalsoverviewTgeneticamyotrophiclater">Table 2a</a>), followed by the remaining in alphabetic order (<a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later_1/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater1" rid-ob="figobalsoverviewTgeneticamyotrophiclater1">Table 2b</a>).</p><div id="als-overview.T.genetic_amyotrophic_later" class="table"><h3><span class="label">Table 2a. </span></h3><div class="caption"><p>Genetic Amyotrophic Lateral Sclerosis: Most Common Genes and Associated Clinical Features</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__als-overview.T.genetic_amyotrophic_later_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">% of:</th><th id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_3" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4" colspan="4" scope="colgroup" rowspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Associated Phenotype(s)</th><th id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_5" rowspan="2" scope="col" colspan="1" headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_5" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Onset/Penetrance</th><th id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_6" rowspan="2" scope="col" colspan="1" headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_6" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Other Clinical Features / Comments</th></tr><tr><th headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2" id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">ALS w/family history</th><th headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2" id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_2" scope="col" rowspan="1" colspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Simplex ALS</th><th headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4" id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_3" colspan="1" scope="colgroup" rowspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">ALS</th><th headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4" id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_4" scope="col" rowspan="1" colspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">ALS/<br />FTD</th><th headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4" id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_5" scope="col" rowspan="1" colspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">FTD</th><th headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4" id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_6" scope="col" rowspan="1" colspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Other</th></tr></thead><tbody><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>C9orf72</i><br />(<a href="/books/n/gene/als-ftd/"><i>C9orf72</i>- ALS/FTD</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">39%-45%</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%-7%</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>PLS</div></li><li class="half_rhythm"><div>PSP</div></li><li class="half_rhythm"><div>Psychiatric symptoms</div></li><li class="half_rhythm"><div>Parkinsonism</div></li><li class="half_rhythm"><div>Chorea</div></li></ul>
</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>50% are symptomatic by age 58 yrs.</div></li><li class="half_rhythm"><div>~100% by 80 yrs</div></li></ul>
</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assoc w/bvFTD</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SOD1</i><br />(OMIM <a href="https://omim.org/entry/105400" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">105400</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15%-20%</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />AR</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>50% symptomatic by age 46 yrs&#x000a0;<sup>1</sup></div></li><li class="half_rhythm"><div>90% by 70 yrs</div></li></ul>
</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 report of cognitive involvement (assoc w/Ile113Thr variant)&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FUS</i><br />(OMIM <a href="https://omim.org/entry/608030" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">608030</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~4%-8%</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Very rare</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Parkinsonism</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Earlier average onset than <i>SOD1</i>-ALS &#x00026; <i>C9orf72</i>-ALS</div></li><li class="half_rhythm"><div>50%-70% symptomatic by age 51</div></li><li class="half_rhythm"><div>&#x0003e;90% by 71 yrs</div></li></ul>
</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>ALS occurs w/or w/out mild cognitive impairment.</div></li><li class="half_rhythm"><div>1/3 of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have bulbar onset.</div></li><li class="half_rhythm"><div>More common in Asian cohorts</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TARDBP</i> (<i>TDP-43</i>)<br />(<a href="/books/n/gene/tardbp-als/"><i>TARDBP</i>-ALS</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%-4%</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yes</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_4 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mean onset age 53.5 &#x000b1;12 yrs</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; ALS = amyotrophic lateral sclerosis; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; bvFTD = behavioral variant of FTD; FTD = frontotemporal dementia; LMN = lower motor neuron; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; PLS = primary lateral sclerosis; PSP = progressive supranuclear palsy; UMN = upper motor neuron</p></div></dd><dt></dt><dd><div><p class="no_margin">1<i>. SOD1</i> variants other than p.Ala4Val may have a wide range of disease duration within the same family.</p></div></dd><dt>2. </dt><dd><div id="als-overview.TF.2a.1"><p class="no_margin"><a class="bk_pop" href="#als-overview.REF.katz.2012.567">Katz et al [2012]</a></p></div></dd></dl></div></div></div><div id="als-overview.Notable_Variants"><h3>Notable Variants</h3><p><b><i>C9orf72</i>.</b> Expansion of a noncoding GGGGCC hexanucleotide repeat is causative. The exact repeat size that is pathogenic is not firmly established: &#x0003e;60 repeats is widely accepted, although &#x0003e;23 was deemed sufficient in recent meta-analysis [<a class="bk_pop" href="#als-overview.REF.iacoangeli.2019.115">Iacoangeli et al 2019</a>].</p><p><b><i>SOD1</i></b> (Note: Nomenclature of variants is gradually being adjusted to reflect inclusion of the first codon in identification of location [i.e., Ala4Val is now referred to as Ala5Val].)</p><ul><li class="half_rhythm"><div><b>p.Ala4Val</b> is the most common North American variant and is associated with death within 12 to 18 months after symptom onset. ALS associated with this variant may be LMN predominant.</div></li><li class="half_rhythm"><div><b>p.Asp90Ala.</b> Heterozygous northern Swedish and Finnish individuals remain unaffected; <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> northern Swedish and Finnish individuals develop <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> ALS. Individuals NOT of northern Swedish or Finnish origin who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for this variant have a slowly progressive course and reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, and may present with ataxia (compound heterozygotes have also been reported).</div></li><li class="half_rhythm"><div><b>p.Ile113Tthr</b> is associated with reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, later onset, and longer survival [<a class="bk_pop" href="#als-overview.REF.lopate.2010.232">Lopate et al 2010</a>].</div></li></ul><p><b><i>FUS.</i></b> The p.Ser513Pro and p.Arg514Ser variants are associated with later ages of onset (51-62 years) and p.Ser513Pro with longer disease duration (84-156 months) than other FUS variants [<a class="bk_pop" href="#als-overview.REF.akiyama.2016.398">Akiyama et al 2016</a>].</p><p><b><i>TARDBP</i></b> (<i>TDP-43</i>)<i>.</i> The variant p.Gly298Ser is associated with earlier onset and 24-month survival.</p><div id="als-overview.T.genetic_amyotrophic_later_1" class="table"><h3><span class="label">Table 2b. </span></h3><div class="caption"><p>Genetic Amyotrophic Lateral Sclerosis: Less Common Genes and Associated Clinical Features</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later_1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__als-overview.T.genetic_amyotrophic_later_1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3" colspan="4" scope="colgroup" rowspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Associated Phenotype(s)</th><th id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="2" scope="col" colspan="1" headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Other Clinical Features / Comments</th></tr><tr><th headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3" id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">ALS</th><th headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3" id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" scope="col" rowspan="1" colspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">ALS/<br />FTD</th><th headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3" id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" scope="col" rowspan="1" colspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">FTD</th><th headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3" id="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" scope="col" rowspan="1" colspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Other</th></tr></thead><tbody><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ALS2</i> (<a href="https://www.ncbi.nlm.nih.gov/books/NBK1243/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><i>ALS2</i>-ALS</a>)&#x000a0;<sup>2</sup></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PLS</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>ALS is UMN-predominant.</div></li><li class="half_rhythm"><div>Onset from infancy to mid-childhood</div></li><li class="half_rhythm"><div>Long course: bedridden by age 12-50</div></li><li class="half_rhythm"><div>Not observed in adult-onset ALS</div></li><li class="half_rhythm"><div>Reported in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ANG</i> (OMIM <a href="https://omim.org/entry/611895" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">611895</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">? AD&#x000a0;<sup>3</sup></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Parkinson disease</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Phenotype is primarily ALS (may present as FTD or parkinsonism).</div></li><li class="half_rhythm"><div>To date, primarily limited to families of European ancestry&#x000a0;<sup>4</sup></div></li><li class="half_rhythm"><div>Reported in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ANXA11</i> (OMIM <a href="https://omim.org/entry/617839" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">617839</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reported in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFAP410</i> (<i>C21orf2</i>)&#x000a0;<sup>5</sup></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD&#x000a0;<sup>3</sup></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reported in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CHCHD10</i>&#x000a0;<sup>6</sup> (OMIM <a href="https://omim.org/entry/615911" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615911</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Cerebellar ataxia or myopathy</div></li><li class="half_rhythm"><div>Reported in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS only</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CHMP2B</i> (OMIM <a href="https://omim.org/entry/614696" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">614696</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>ALS is more often LMN-predominant.</div></li><li class="half_rhythm"><div>Reported in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS only</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DAO</i> (OMIM <a href="https://omim.org/entry/124050" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">124050</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reported in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS only</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DCTN1</i>&#x000a0;<sup>7</sup> (OMIM <a href="https://omim.org/entry/601143" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">601143</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD&#x000a0;<sup>3</sup></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reported in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS only</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERBB4</i> (OMIM <a href="https://omim.org/entry/615515" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615515</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reported in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FIG4</i>&#x000a0;<sup>8</sup> (OMIM <a href="https://omim.org/entry/612577" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612577</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Normal NCVs; limited LMN involvement on EMG</div></li><li class="half_rhythm"><div>Reported in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HNRNPA1</i>&#x000a0;<sup>9</sup> (OMIM <a href="https://omim.org/entry/615426" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615426</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD&#x000a0;<sup>3</sup></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reported in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MATR3</i>&#x000a0;<sup>10</sup> (OMIM <a href="https://omim.org/entry/606070" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">606070</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PLS</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reported in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS only</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MOBP</i>&#x000a0;<sup>11</sup></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 3</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reported in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NEK1</i> (OMIM <a href="https://omim.org/entry/617892" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">617892</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD&#x000a0;<sup>3</sup></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>ALS occurs w/or w/out cognitive impairment.</div></li><li class="half_rhythm"><div>Reported in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>OPTN</i>&#x000a0;<sup>12</sup> (OMIM <a href="https://omim.org/entry/613435" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613435</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>ALS is characterized by slow progression &#x00026; extended duration.</div></li><li class="half_rhythm"><div>Reported in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PFN1</i> (OMIM <a href="https://omim.org/entry/614808" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">614808</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Features of Miller-Dieker syndrome noted in a few <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SCFD1</i>&#x000a0;<sup>11</sup></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 3</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reported in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SETX</i> (OMIM <a href="https://omim.org/entry/602433" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">602433</a>)&#x000a0;<sup>13</sup></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>1st decade to adult onset; most commonly in adolescence (juvenile ALS)</div></li><li class="half_rhythm"><div>Also referred to as distal hereditary motor neuropathy</div></li><li class="half_rhythm"><div>No bulbar involvement</div></li><li class="half_rhythm"><div>Reported in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS only</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SPG11</i> (<i>spatacsin</i>)&#x000a0;<sup>14</sup> (OMIM <a href="https://omim.org/entry/602099" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">602099</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Juvenile ALS w/onset in 1st or 2nd decade; very slowly progressive</div></li><li class="half_rhythm"><div>Multiple ethnicities; often <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> parents</div></li><li class="half_rhythm"><div>Cognitive impairment not reported</div></li><li class="half_rhythm"><div>Thin corpus callosum not reported</div></li><li class="half_rhythm"><div>Reported in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS only</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SQSTM1</i> (OMIM <a href="https://omim.org/entry/616437" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616437</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Paget disease</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div><i>SQSTM1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in individuals w/<i>SOD1</i>-ALS, <i>FUS</i>-ALS, Lewy body dementia, &#x00026; Alzheimer dementia.</div></li><li class="half_rhythm"><div>Reported in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS (<i>SQSTM1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in &#x02264;4% of simplex ALS)</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TAF15</i>&#x000a0;<sup>15</sup></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 3</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reported in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS only</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TBK1</i> (OMIM <a href="https://omim.org/entry/616439" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616439</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>ALS occurs w/or w/out mild cognitive impairment.</div></li><li class="half_rhythm"><div><i>TBK1</i> pathogenic variants identified in a few individuals w/<i>OPTN</i>-ALS &#x00026; <i>FUS</i>-ALS.</div></li><li class="half_rhythm"><div>Reported in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TUBA4A</i> (OMIM <a href="https://omim.org/entry/616208" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616208</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reported in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>UBQLN2</i> (OMIM <a href="https://omim.org/entry/300857" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">300857</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PLS; spastic paraparesis</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Onset from childhood to late adulthood</div></li><li class="half_rhythm"><div>Reported in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS only</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>UNC13A</i>&#x000a0;<sup>15</sup></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 3</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reported in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS only</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>VAPB</i>&#x000a0;<sup>16</sup><i><sup>,</sup></i>&#x000a0;<sup>17</sup> (OMIM <a href="https://omim.org/entry/608627" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">608627</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>ALS occurs w/or w/out postural tremor.</div></li><li class="half_rhythm"><div>To date, reported primarily in Brazilians&#x000a0;<sup>17</sup> &#x00026; Japanese</div></li><li class="half_rhythm"><div>Reported in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS only</div></li></ul>
</td></tr><tr><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>VCP</i>&#x000a0;<sup>18</sup> (OMIM <a href="https://omim.org/entry/613954" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613954</a>)</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_3 hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Paget disease</td><td headers="hd_h_als-overview.T.genetic_amyotrophic_later_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>ALS occurs w/or w/o mild cognitive impairment.</div></li><li class="half_rhythm"><div>Clinical course may be rapid.</div></li><li class="half_rhythm"><div>May include parkinsonism</div></li><li class="half_rhythm"><div>Reported in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS only</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; ALS = amyotrophic lateral sclerosis; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; EMG = electromyography; FTD = frontotemporal dementia; LMN = lower motor neuron; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; NCV = nerve conduction velocity; PLS = primary lateral sclerosis; UMN = upper motor neuron; XLD = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="als-overview.TF.2b.1"><p class="no_margin">Genes are listed alphabetically.</p></div></dd><dt>2. </dt><dd><div id="als-overview.TF.2b.2"><p class="no_margin"><i>ALS2</i>: long protein transcript results in primary lateral sclerosis, short transcript produces ALS.</p></div></dd><dt>3. </dt><dd><div id="als-overview.TF.2b.3"><p class="no_margin">Susceptibility <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (i.e., a genetic variant that increases a person's predisposition for developing a given disorder)</p></div></dd><dt>4. </dt><dd><div id="als-overview.TF.2b.4"><p class="no_margin"><a class="bk_pop" href="#als-overview.REF.ryan.2019b.659">Ryan et al [2019b]</a></p></div></dd><dt>5. </dt><dd><div id="als-overview.TF.2b.5"><p class="no_margin"><a class="bk_pop" href="#als-overview.REF.chia.2018.94">Chia et al [2018]</a></p></div></dd><dt>6. </dt><dd><div id="als-overview.TF.2b.6"><p class="no_margin"><i>CHCHD10</i> allelic disorders: mitochondrial myopathy and late-onset spinal motor neuronopathy (see <a href="/books/n/gene/chchd10-dis/"><i>CHCHD10</i>-Related Disorders</a>)</p></div></dd><dt>7. </dt><dd><div id="als-overview.TF.2b.7"><p class="no_margin"><i>DCTN1 a</i>llelic disorders: distal hereditary motor neuronopathy with vocal cord paresis and <a href="/books/n/gene/perry/">Perry syndrome</a></p></div></dd><dt>8. </dt><dd><div id="als-overview.TF.2b.8"><p class="no_margin"><i>FIG4</i> allelic disorder: <a href="/books/n/gene/cmt/">Charcot-Marie Tooth (CMT) hereditary neuropathy</a></p></div></dd><dt>9. </dt><dd><div id="als-overview.TF.2b.9"><p class="no_margin"><i>HNRNPA1</i> allelic disorder: <a href="/books/n/gene/ibmpfd/">inclusion body myopathy with Paget disease of bone and/or frontotemporal dementia</a></p></div></dd><dt>10. </dt><dd><div id="als-overview.TF.2b.10"><p class="no_margin"><i>MATR3</i> allelic disorder: vocal cord and pharyngeal dysfunction with distal myopathy</p></div></dd><dt>11. </dt><dd><div id="als-overview.TF.2b.11"><p class="no_margin"><a class="bk_pop" href="#als-overview.REF.van_rheenen.2016.1043">van Rheenen et al [2016]</a></p></div></dd><dt>12. </dt><dd><div id="als-overview.TF.2b.12"><p class="no_margin"><i>OPTN</i> allelic disorder: primary open angle glaucoma</p></div></dd><dt>13. </dt><dd><div id="als-overview.TF.2b.13"><p class="no_margin"><i>SETX</i> allelic disorder: <a href="/books/n/gene/aoa2/">ataxia with oculomotor apraxia type 2</a></p></div></dd><dt>14. </dt><dd><div id="als-overview.TF.2b.14"><p class="no_margin"><i>SPG11</i> allelic disorders: <a href="/books/n/gene/spg11/">spastic paraplegia 11</a> (with mild intellectual disability and thin corpus callosum) and <a href="/books/n/gene/cmt/">CMT</a></p></div></dd><dt>15. </dt><dd><div id="als-overview.TF.2b.15"><p class="no_margin"><a class="bk_pop" href="#als-overview.REF.brown.2017.162">Brown &#x00026; Al-Chalabi [2017]</a></p></div></dd><dt>16. </dt><dd><div id="als-overview.TF.2b.16"><p class="no_margin"><i>VAPB</i> allelic disorder: adult-onset spinal muscular atrophy, Finkel type</p></div></dd><dt>17. </dt><dd><div id="als-overview.TF.2b.17"><p class="no_margin"><i>VAPB</i> <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> p.Pro56Ser identified in individuals of Portuguese/Brazilian &#x00026; African/Brazilian descent</p></div></dd><dt>18. </dt><dd><div id="als-overview.TF.2b.18"><p class="no_margin"><i>VCP</i> allelic disorder: <a href="/books/n/gene/ibmpfd/">inclusion body myopathy, Paget disease, and frontotemporal dementia</a> (IBMPFD)</p></div></dd></dl></div></div></div></div><div id="als-overview.Simplex_ALS"><h3>Simplex ALS</h3><p>About 85% of ALS occurs in individuals with no family history of ALS; in common parlance such individuals are often said to have "<a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a>" ALS. ALS that occurs within a family with a known history of ALS but no known genetic cause yet identified may be called "<a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS without a known cause."</p><p>It is possible that genetic ALS or <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS of unknown cause may <b>appear to be</b> <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS when there is markedly decreased <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of an ALS-causing genetic variant. One must also consider the possibility that other diagnoses within a family may reflect a genetic cause, particularly the presence of FTD or Paget disease of bone (see <a class="figpopup" href="/books/NBK1450/table/als-overview.T.singlegene_disorders_of_i/?report=objectonly" target="object" rid-figpopup="figalsoverviewTsinglegenedisordersofi" rid-ob="figobalsoverviewTsinglegenedisordersofi">Table 1</a>).</p><p>The etiology of <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS is not well understood. It has long been thought to be <a class="def" href="/books/n/gene/glossary/def-item/multifactorial/">multifactorial</a>, with both susceptibility genes and multiple environmental factors contributing.</p><ul><li class="half_rhythm"><div>Genome-wide association studies (GWAS) have not yielded the anticipated results, although the 60% heritability reported in a twin study would suggest that complex genetics plays a large role [<a class="bk_pop" href="#als-overview.REF.alchalabi.2010.1324">Al-Chalabi et al 2010</a>].</div></li><li class="half_rhythm"><div>A study of heritability in the Irish population reported that genetic factors account for nearly 40% of the variation in risk for developing ALS in individuals who did not have disease-causing variants in known ALS genes [<a class="bk_pop" href="#als-overview.REF.ryan.2019a.1001">Ryan et al 2019a</a>].</div></li><li class="half_rhythm"><div>Variants in several genes have been identified as modifiers of disease onset or course:</div><ul><li class="half_rhythm"><div><i>APOE-2</i> is associated with a later age of onset [<a class="bk_pop" href="#als-overview.REF.li.2004.209">Li et al 2004</a>].</div></li><li class="half_rhythm"><div><i>VEGF</i> is associated with more rapid disease progression [<a class="bk_pop" href="#als-overview.REF.lambrechts.2003.383">Lambrechts et al 2003</a>].</div></li><li class="half_rhythm"><div>31 or more polyQ repeats in <i>ATXN2</i> is associated with spinal onset and shorter survival [<a class="bk_pop" href="#als-overview.REF.borghero.2015.2906.e1">Borghero et al 2015</a>].</div></li><li class="half_rhythm"><div>Variants in several other genes have been shown to reduce risk for ALS, including variants in <i>SMN2</i> and variants in <i>CHGB</i> and <i>PGC-1a</i> [<a class="bk_pop" href="#als-overview.REF.ohta.2016.4771">Ohta et al 2016</a>].</div></li></ul></li><li class="half_rhythm"><div>Statistical analysis of more than 6,000 European cases of ALS suggests that the disease may develop as the result of a series of six "steps" &#x02013; some genetic and some environmental &#x02013; that occur over time [<a class="bk_pop" href="#als-overview.REF.alchalabi.2014.1108">Al-Chalabi et al 2014</a>].</div></li></ul></div></div><div id="als-overview._escape__3_Evaluation_Strat"><h2 id="_als-overview__escape__3_Evaluation_Strat_">3. Evaluation Strategies to Identify the Genetic Cause of ALS in a Proband</h2><p>Establishing a specific genetic cause of ALS:</p><ul><li class="half_rhythm"><div>Can aid in discussions of prognosis (which are beyond the scope of this <i>GeneReview</i>) and <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>;</div></li><li class="half_rhythm"><div>Usually involves a medical history, physical examination, laboratory testing, family history, and <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a>/genetic testing.</div></li></ul><p><b>Medical history.</b> Very rapid progression of symptoms raises suspicion of <i>SOD1-</i>ALS caused by the p.Ala4Val variant. See <a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater" rid-ob="figobalsoverviewTgeneticamyotrophiclater">Table 2a</a>.</p><p><b>Physical examination.</b> An absent ankle reflex in the presence of subacute weakness of the leg may be an early sign in <i>SOD1</i>-ALS [T Siddique, personal observation].</p><p><b>Family history.</b> A three-generation family history should be obtained, with attention paid to relatives with neurologic signs and symptoms, particularly cognitive impairment, remembering that in the past it was less common for practitioners to distinguish FTD from other dementias. Note should be made of parkinsonism, psychiatric illness, and Paget disease as well. Documentation of relevant findings in family members may be accomplished either through direct examination of those individuals or by review of their medical records, including the results of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, neuroimaging studies, and autopsy examinations.</p><p><b>Molecular genetic testing</b> approaches can include a combination of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing (<a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>, or <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>). Gene-targeted testing requires the clinician to hypothesize as to which gene(s) are likely involved, whereas genomic testing does not.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes the four genes that most commonly cause ALS and some or all of the genes listed in <a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater" rid-ob="figobalsoverviewTgeneticamyotrophiclater">Tables 2a</a> and <a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later_1/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater1" rid-ob="figobalsoverviewTgeneticamyotrophiclater1">2b</a> is most likely to identify the genetic cause of ALS at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with ALS. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><ul><li class="half_rhythm"><div class="half_rhythm"><b>Comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) may be considered. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</div><div class="half_rhythm">If <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is not diagnostic, <b><a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a></b> (when clinically available) may be considered to detect (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul></div><div id="als-overview._escape__4_Genetic_Counseli"><h2 id="_als-overview__escape__4_Genetic_Counseli_">4. Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><p>Genetic counseling for individuals with amyotrophic lateral sclerosis (ALS) and their families is reviewed for the following clinical contexts:</p><ul><li class="half_rhythm"><div><b>Genetic ALS.</b> ALS resulting from a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a known ALS <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> regardless of family history (see <a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater" rid-ob="figobalsoverviewTgeneticamyotrophiclater">Tables 2a</a> and <a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later_1/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater1" rid-ob="figobalsoverviewTgeneticamyotrophiclater1">2b</a>)</div></li><li class="half_rhythm"><div><b>ALS of unknown cause.</b> The cause may be unknown because <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> either has not been performed or did not identify a genetic cause (see <a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater" rid-ob="figobalsoverviewTgeneticamyotrophiclater">Tables 2a</a> and <a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later_1/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater1" rid-ob="figobalsoverviewTgeneticamyotrophiclater1">2b</a>). ALS of unknown cause can either be "<a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a>" (i.e., occur in families with two or more close relatives with ALS) or can occur in a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in family).</div></li></ul><div id="als-overview.Genetic_ALS"><h3>Genetic ALS</h3><div id="als-overview.Mode_of_Inheritance"><h4>Mode of Inheritance</h4><p><b>Genetic ALS</b> can be inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>, or <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner (see <a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater" rid-ob="figobalsoverviewTgeneticamyotrophiclater">Tables 2a</a> and <a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later_1/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater1" rid-ob="figobalsoverviewTgeneticamyotrophiclater1">2b</a>). Determination of the <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a> is based on family history and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div id="als-overview.Autosomal_Dominant_ALS__Ris"><h4>Autosomal Dominant ALS &#x02013; Risk to Family Members</h4><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> ALS have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with adult-onset ALS may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by <i>de novo</i> pathogenic variants is unknown; only a handful have been reported [<a class="bk_pop" href="#als-overview.REF.chi_.2011.553.e23">Chi&#x000f2; et al 2011</a>].</div></li><li class="half_rhythm"><div>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can be offered <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>; however, molecular genetic testing should be performed in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>, as it would be considered predictive genetic testing.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Though theoretically possible, no clear instances of germline mosaicism have been reported.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with ALS may appear to be negative because of failure to recognize it or another disorder (e.g., FTD, Paget disease of bone) caused by the same disease variant in family members, reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, early death of the parent before the onset of symptoms, or late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the clinical/genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or is known to have the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the proband, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a known ALS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that cannot be detected in the leukocyte DNA of either parent, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is estimated to be 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#als-overview.REF.rahbari.2016.126">Rahbari et al 2016</a>].</div></li><li class="half_rhythm"><div>If the parents have not been tested for the ALS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> but are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low. However, sibs of a proband with clinically unaffected parents are still presumed to be at increased risk for ALS because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent or the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#als-overview.REF.rahbari.2016.126">Rahbari et al 2016</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> ALS has a 50% chance of inheriting the ALS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or has the ALS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="als-overview.Autosomal_Recessive_ALS__Ri"><h4>Autosomal Recessive ALS &#x02013; Risk to Family Members</h4><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an individual diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> ALS are obligate heterozygotes (i.e., carriers of one ALS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib has a 25% chance of inheriting two copies of the disease-causing genetic variant and later developing the disease, a 50% chance of inheriting one copy of the disease-causing variant (i.e, being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>), and a 25% chance of inheriting two copies of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> without the disease-causing variant so that (s)he is neither <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> nor a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes remain asymptomatic, but with each of their children they have a 50% chance of passing on the disease-causing variant.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> ALS are obligate heterozygotes (carriers) for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an ALS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Carrier (<a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a>) detection.</b> Carrier testing for at-risk relatives requires prior identification of the ALS pathogenic variants in the family.</p></div><div id="als-overview.XLinked_ALS__Risk_to_Family"><h4>X-Linked ALS &#x02013; Risk to Family Members</h4><p>To date, <i>UBQLN2</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> known to be associated with ALS; both <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> males and <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females (possibly at a later age depending on <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>) will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>A male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may have inherited the <i>UBQLN2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from his mother (who may or may not be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>), or the pathogenic variant may be <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>. (Note: The father of a male with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> ALS will not have the disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>UBQLN2</i> pathogenic variant.)</div></li><li class="half_rhythm"><div>A female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may have inherited the <i>UBQLN2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from either her mother or her father (who may or may not be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>), or the pathogenic variant may be <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to sibs of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the mother: if the mother of the proband has the <i>UBQLN2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%.</div></li><li class="half_rhythm"><div>The risk to sibs of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the parents. If the mother of the proband has a <i>UBQLN2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. If the father of the proband has the <i>UBQLN2</i> pathogenic variant, he will transmit it to all of his daughters and none of his sons.</div></li><li class="half_rhythm"><div>Male and female offspring who inherit a <i>UBQLN2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> if they live long enough, although female offspring who inherit the pathogenic variant may have favorably skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> resulting in later onset of disease.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Affected males transmit the <i>UBQLN2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to <b>all</b> of their daughters, who will be heterozygotes, and <b>none</b> of their sons; <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> females have a 50% chance of transmitting the pathogenic variant to each child, regardless of the child's gender.</p><p><b>Other family members.</b> The risk to other family members depends on the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has the <i>UBQLN2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div></div><div id="als-overview.ALS_of_Unknown_Cause"><h3>ALS of Unknown Cause</h3><p><b>Familial ALS.</b> As noted in <a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater" rid-ob="figobalsoverviewTgeneticamyotrophiclater">Tables 2a</a> and <a class="figpopup" href="/books/NBK1450/table/als-overview.T.genetic_amyotrophic_later_1/?report=objectonly" target="object" rid-figpopup="figalsoverviewTgeneticamyotrophiclater1" rid-ob="figobalsoverviewTgeneticamyotrophiclater1">2b</a>, virtually all adult-onset genetic ALS is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner, with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> <i>UBQLN2-</i>ALS being the only exception. If the family history is sufficient to allow identification of autosomal dominant transmission (evidence of parent-to-child transmission of disease, transmission of disease from father to son if there is an opportunity), the risk to other family members is the same as described in <a href="#als-overview.Autosomal_Dominant_ALS__Ris">Autosomal Dominant ALS &#x02013; Risk to Family Members</a>.</p><p>Even if the <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a> cannot be firmly established, the risk of inheriting the disease-causing variant is likely to follow an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> pattern, given what is known to date about genetic ALS. However, it is also quite likely that the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of some variants may be reduced, making it more difficult to predict which persons will go on to develop disease.</p><p>Given what is known about ALS-related genes, when FTD or Paget disease is present in the family (even if not manifest in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>), it is reasonable to assume that those individuals are also <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the variant identified in the person with ALS and, thus, have the same genetic risk of passing the variant on to their children.</p><p>Most ALS disease-causing variants identified to date have at least some <a class="def" href="/books/n/gene/glossary/def-item/intrafamilial-variability/">intrafamilial variability</a> in terms of age of onset, site of onset, and disease duration.</p><p><b>Simplex ALS.</b> Lifetime risk of developing ALS is estimated at 1:350 for men and 1:500 for women.</p><p>As noted in <b>Familial ALS</b>, the presence of FTD and/or Paget disease in other near relatives should raise concern that this is <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> disease.</p></div><div id="als-overview.Related_Genetic_Counseling"><h3>Related Genetic Counseling Issues</h3><p><b>Predictive testing (i.e., testing of asymptomatic at-risk individuals)</b></p><ul><li class="half_rhythm"><div>Predictive testing for at-risk relatives is possible once the ALS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member.</div></li><li class="half_rhythm"><div>Potential consequences of such testing (including, but not limited to, socioeconomic changes, the need for long-term follow up and evaluation arrangements for individuals with a positive test result) as well as the capabilities and limitations of predictive testing should be discussed in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> prior to testing.</div></li></ul><p><b>Predictive testing in minors (i.e., testing of asymptomatic at-risk individuals age &#x0003c;18 years)</b></p><ul><li class="half_rhythm"><div>For asymptomatic minors at risk for adult-onset conditions for which early treatment would have no beneficial effect on disease morbidity and mortality, predictive genetic testing is considered inappropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</div></li><li class="half_rhythm"><div>For more information, see the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</div></li></ul><p>In a family with an established diagnosis of ALS, it is appropriate to consider testing of symptomatic individuals regardless of age.</p></div></div><div id="als-overview.Resources"><h2 id="_als-overview_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Amyotrophic Lateral Sclerosis Association (ALS Association)</b></div><div>27001 Agoura Road</div><div>Suite 250</div><div>Calabasas Hills CA 91301-5104</div><div><b>Phone:</b> 800-782-4747 (Toll-free Patient Services); 818-880-9007</div><div><b>Fax:</b> 818-880-9006</div><div><b>Email:</b> alsinfo@alsa-national.org</div><div><a href="http://www.alsa.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.alsa.org</a></div></li><li class="half_rhythm"><div><b>Amyotrophic Lateral Sclerosis Society of Canada</b></div><div>3000 Steeles Avenue East</div><div>Suite 200</div><div>Markham Ontario L3R 4T9</div><div>Canada</div><div><b>Phone:</b> 800-267-4257 (toll-free); 905-248-2052</div><div><b>Fax:</b> 905-248-2019</div><div><a href="http://www.als.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.als.ca</a></div></li><li class="half_rhythm"><div><b>Les Turner ALS Foundation (Amyotrophic Lateral Sclerosis)</b></div><div>5550 West Touhy Avenue</div><div>Suite 302</div><div>Skokie IL 60077-3254</div><div><b>Phone:</b> 888-257-1107 (toll-free); 847-679-3311</div><div><b>Fax:</b> 847-679-9109</div><div><b>Email:</b> info@lesturnerals.org</div><div><a href="http://www.lesturnerals.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.lesturnerals.org</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy Association - USA (MDA-ALS Division)</b></div><div>222 S. Riverside Plaza </div><div>Suite 1500</div><div>Chicago IL 60606</div><div><b>Phone:</b> 800-344-4863 (toll-free); 800-572-1717 (toll-free)</div><div><b>Email:</b> mda@mdausa.org</div><div><a href="https://www.mda.org/sites/default/files/MDA-ALS-Fact-Sheet-Flyer-FINAL.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mda.org/sites/default/files/MDA-ALS-Fact-Sheet-Flyer-FINAL.pdf</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Amyotrophic%20lateral%20sclerosis&#x00026;parent=Carrier%20Status&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Amyotrophic lateral sclerosis</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/amyotrophic-lateral-sclerosis" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Amyotrophic lateral sclerosis</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22225/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Amyotrophic lateral sclerosis</a></div></li><li class="half_rhythm"><div><b>Motor Neurone Disease Association</b></div><div>PO Box 246</div><div>Northampton NN1 2PR</div><div>United Kingdom</div><div><b>Phone:</b> 01604250505</div><div><b>Fax:</b> 01604 624726/638289</div><div><b>Email:</b> enquiries@mndassociation.org</div><div><a href="http://www.mndassociation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mndassociation.org</a></div></li><li class="half_rhythm"><div><b>National Amyotrophic Lateral Sclerosis (ALS) Registry</b></div><div>Agency for Toxic Substances and Disease Registry</div><div>4770 Buford Highway Northeast</div><div>Atlanta GA 30341</div><div><b>Phone:</b> 800-232-4636</div><div><b>Email:</b> cdcinfo@cdc.gov</div><div><a href="http://wwwn.cdc.gov/als/?s_cid=als_001" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">National ALS Registry</a></div></li></ul></div><div id="als-overview._escape__5_Management_of_AL"><h2 id="_als-overview__escape__5_Management_of_AL_">5. Management of ALS</h2><p>Treatment is palliative.</p><p>Many individuals benefit from care by a multidisciplinary team that includes a neurologist, specially trained nurses, pulmonologist, speech therapist, physical therapist, occupational therapist, respiratory therapist, nutritionist, psychologist, social worker, and genetic counselor. Data suggest that individuals under the care of such a team may have a better prognosis [<a class="bk_pop" href="#als-overview.REF.van_den_berg.2004.226">van den Berg et al 2004</a>, <a class="bk_pop" href="#als-overview.REF.andersen.2005.921">Andersen et al 2005</a>]. Factors that influence survival include age, forced vital capacity, fatigue, body strength, spasticity, depression, and household income [<a class="bk_pop" href="#als-overview.REF.paillisse.2005.37">Paillisse et al 2005</a>], most of which can be managed by the appropriate specialist in the multidisciplinary team.</p><p>The following two drugs are currently approved by the FDA for treatment of ALS:</p><ul><li class="half_rhythm"><div><b>Riluzole,</b> now available both in tablet form as Rilutek<sup>&#x000ae;</sup> and as the oral suspension Teglutik<sup>&#x000ae;</sup>, appropriate for use in feeding tubes. Clinical trials with riluzole demonstrated marginal slowing of disease progression in some but not all patients [<a class="bk_pop" href="#als-overview.REF.riviere.1998.526">Riviere et al 1998</a>]. Rilutek is thought to act by inhibiting the production of glutamate, a neurotransmitter that has been theorized to be the initiator of a series of molecular events that damage neurons. Riluzole is associated with elevation of serum alanine aminotransferase levels in 10%-15% of treated individuals; in rare instances it may cause bone marrow depression [<a class="bk_pop" href="#als-overview.REF.bensimon.2004.525">Bensimon &#x00026; Doble 2004</a>].</div></li><li class="half_rhythm"><div><b>Edaravone</b> (trade name Radicava<sup>&#x02122;</sup>), approved in 2017 for use in patients with probable or definite ALS who are early in the course of their illness. Edaravone is given by slow intravenous infusion on the first 10-14 days of a 28-day cycle. Because it contains sodium bisulfite, it should not be given to patients with sulfite sensitivity. Edaravone is a free radical scavenger, originally developed for use in treatment of stroke patients. In Phase III trials, the most positive effect reported in ALS Functional Rating Scale (revised) scores was observed in patients with preserved vital capacities who had been symptomatic a relatively short time and were concurrently taking riluzole. Therefore, combination therapy should be considered early in the illness [<a class="bk_pop" href="#als-overview.REF.sawada.2017.735">Sawada 2017</a>].</div></li></ul><p>A Phase III clinical trial is currently under way for patients with <i>SOD1</i>-ALS to evaluate the effects of an antisense oligonucleotide designed to bind with <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> to reduce the SOD (superoxide dismutase) load. See ClinicalTrials.gov study <a href="https://www.clinicaltrials.gov/ct2/show/NCT02623699" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NCT02623699</a>.</p><div id="als-overview.Symptom_Management"><h3>Symptom Management</h3><p>Oral secretions in individuals with bulbar symptoms can be reduced with tricylic antidepressants and anticholinergic agents, thus reducing the need for suctioning.</p><p>Pseudobulbar affect can be managed with antidepressants such as Nuedexta<sup>&#x000ae;</sup> (dextromethophan and quinidine).</p><p>Swallowing difficulties can be alleviated by thickening liquids and pureeing solid food, as well as eventually using a gastrostomy tube to help maintain caloric intake and hydration. Nutritional management, a prognostic factor for survival, has become a focus in the clinical setting.</p><p>Medications such as baclofen and benzodiazepines can help relieve spasticity and muscle cramps; however, weakness and lethargy are common side effects. Individualized moderate-intensity endurance-type exercises for the trunk and limbs may help to reduce spasticity [<a class="bk_pop" href="#als-overview.REF.ashworth.2004.cd004156">Ashworth et al 2004</a>].</p><p>Low-tech (e.g., alphabet board) and high-tech (i.e., computer-assisted) devices can aid speech and communication. The recent development of the eye movement-controlled on-screen keyboard may enable communication for individuals without any remaining limb function.</p><p>Assistive devices, such as walkers or wheelchairs, can aid mobility; and others, such as bathroom installments, hospital bed, and Hoyer lift, can aid in activities of daily living at home.</p><p>Ventilatory assistance may include use of bilevel positive airway pressure, which has played an increasing role in preserving and prolonging quality of life in persons with ALS. In 1999, the American Academy of Neurology published norms recommending the initiation of noninvasive ventilation (NIV) in individuals with a theoretic forced vital capacity (FVC) less than 50% of predicted [<a class="bk_pop" href="#als-overview.REF.miller.1999.1311">Miller et al 1999</a>]. Studies show that mean survival significantly increases when NIV is initiated prior to the onset of bulbar symptoms [<a class="bk_pop" href="#als-overview.REF.farrero.2005.2132">Farrero et al 2005</a>]. Therefore, evaluation by a pulmonologist should be undertaken before FVC falls below 50%.</p><p>Although tracheostomy and ventilatory support can extend life span, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals often decline these interventions [<a class="bk_pop" href="#als-overview.REF.albert.1999.278">Albert et al 1999</a>].</p><p>The tremendous psychological and social impact of ALS on both <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and caregivers needs to be continually addressed [<a class="bk_pop" href="#als-overview.REF.goldstein.1998.s114">Goldstein et al 1998</a>]. Hospice care, typically instituted once FVC is less than 30%, contributes to the individual's comfort in the terminal stages.</p><p>Individuals with ALS commonly supplement their diets with vitamin E, vitamin C, B vitamins, selenium, zinc, coenzyme Q<sub>10</sub>, and herbal preparations such as ginseng, ginkgo biloba, and Maharishi Amrit Kalesh [<a class="bk_pop" href="#als-overview.REF.cameron.2002.631">Cameron &#x00026; Rosenfeld 2002</a>]. In a Cochrane Review, <a class="bk_pop" href="#als-overview.REF.orrell.2007.cd002829">Orrell et al [2007]</a> summarized and evaluated 21 clinical trials of antioxidant therapies in various combinations including: vitamin E, high-dose coenzyme Q<sub>10</sub>, vitamin C, selenium, beta-carotene, N-acetylcysteine, L-methionine, and selegiline. In the majority of these studies, the sample size was not adequate for statistical evaluation. Although the antioxidants were well tolerated in many of the trials, significant differences in longevity, muscle strength, or functional rating scales over time were not identified.</p></div></div><div id="als-overview.References"><h2 id="_als-overview_References_">References</h2><div id="als-overview.Published_Guidelines__Conse"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF1">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 9-27-19. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF2">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2018. Accessed 9-27-19.</div></li></ul></div><div id="als-overview.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.abrahams.2005.321">Abrahams S, Goldstein LH, Suckling J, Ng V, Simmons A, Chitnis X, Atkins L, Williams SC, Leigh PN. Frontotemporal white matter changes in amyotrophic lateral sclerosis. <span><span class="ref-journal">J Neurol. </span>2005;<span class="ref-vol">252</span>:321–31.</span> [<a href="/pubmed/15739047" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15739047</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.abrahams.2014.9">Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. <span><span class="ref-journal">Amyotroph Lateral Scler Frontotemporal Degener. </span>2014;<span class="ref-vol">15</span>:9–14.</span> [<a href="/pubmed/23781974" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23781974</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.akiyama.2016.398">Akiyama T, Warita H, Kato M, Nishiyama A, Izumi R, Ikeda C, Kamada M, Suzuki N, Aoki M. Genotype-phenotype relationships in familial amyotrophic lateral sclerosis with FUS/TLS mutations in Japan. <span><span class="ref-journal">Muscle Nerve. </span>2016;<span class="ref-vol">54</span>:398–404.</span> [<a href="/pubmed/26823199" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26823199</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.albert.1999.278">Albert SM, Murphy PL, Del Bene ML, Rowland LP. A prospective study of preferences and actual treatment choices in ALS. <span><span class="ref-journal">Neurology. </span>1999;<span class="ref-vol">53</span>:278–83.</span> [<a href="/pubmed/10430414" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10430414</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.alchalabi.2014.1108">Al-Chalabi A, Calvo A, Chi&#x000f2; A, Colville S, Ellis CM, Hardiman O, Heverin M, Howard RS, Huisman MHB, Keren N, Leigh PN, Mazzini L, Mora G, Orrell RW, Rooney J, Scott KM, Scotton WJ, Seelen M, Shaw CE, Sidle KS, Swingler R, Tsuda M, Veldink JH, Visser AE, van den Berg LH, Pearce N. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. <span><span class="ref-journal">Lancet Neurol. </span>2014;<span class="ref-vol">13</span>:1108–13.</span> [<a href="/pmc/articles/PMC4197338/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4197338</span></a>] [<a href="/pubmed/25300936" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25300936</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.alchalabi.2010.1324">Al-Chalabi A, Fang F, Hanby MF, Leigh PN, Shaw CE, Ye W, Rijsdijk F. An estimate of amyotrophic lateral sclerosis heritability using twin data. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2010;<span class="ref-vol">81</span>:1324–6.</span> [<a href="/pmc/articles/PMC2988617/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2988617</span></a>] [<a href="/pubmed/20861059" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20861059</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.andersen.2005.921">Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, Pradat PF, Silani V, Tomik B. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. <span><span class="ref-journal">Eur J Neurol. </span>2005;<span class="ref-vol">12</span>:921–38.</span> [<a href="/pubmed/16324086" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16324086</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.ashworth.2004.cd004156">Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2004;<span class="ref-vol">1</span>:CD004156.</span> [<a href="/pubmed/14974059" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14974059</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.beeldman.2016.611">Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, de Haan RJ. The cognitive profile of ALS: a systematic review and meta-analysis. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2016;<span class="ref-vol">87</span>:611–9.</span> [<a href="/pubmed/26283685" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26283685</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.belbasis.2016.96">Belbasis L, Bellouu V, Evangelou E. Environmental risk factors and amyotrophic lateral sclerosis: an umbrella review and critical assessment of current evidence from systematic review and meta-analyses of observational studies. <span><span class="ref-journal">Neuroepidemiology. </span>2016;<span class="ref-vol">46</span>:96–105.</span> [<a href="/pubmed/26731747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26731747</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.bensimon.2004.525">Bensimon G, Doble A. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. <span><span class="ref-journal">Expert Opin Drug Saf. </span>2004;<span class="ref-vol">3</span>:525–34.</span> [<a href="/pubmed/15500412" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15500412</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.bigio.2013.314">Bigio EH. Making the diagnosis of frontotemporal lobar degeneration. <span><span class="ref-journal">Arch Pathol Lab Med. </span>2013;<span class="ref-vol">137</span>:314–25.</span> [<a href="/pmc/articles/PMC3629720/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3629720</span></a>] [<a href="/pubmed/23451743" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23451743</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.borghero.2015.2906.e1">Borghero G, Pugliatti M, Marrosu MG, Floris G, Cannas A, Parish LD, Cua TB, Ticca A, Traccis S, Manera U, Canosa A, Moglia C, Calvo A, Barberis M, Brunetti M, Renton AE, Nails MA, Traynor BJ, Restagno G, Chi&#x000f2; A, et al.  ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. <span><span class="ref-journal">Neurobiol Aging. </span>2015;<span class="ref-vol">36</span>:2906.e1–5.</span> [<a href="/pmc/articles/PMC5193218/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5193218</span></a>] [<a href="/pubmed/26208502" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26208502</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.brooks.2000.293">Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. <span><span class="ref-journal">Amyotroph Lateral Scler Other Motor Neuron Disord. </span>2000;<span class="ref-vol">1</span>:293–9.</span> [<a href="/pubmed/11464847" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11464847</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.brown.2017.162">Brown RH Jr, Al-Chalabi A. Amyotrophic lateral sclerosis. <span><span class="ref-journal">N Engl J Med. </span>2017;<span class="ref-vol">377</span>:162–72.</span> [<a href="/pubmed/28700839" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28700839</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.cameron.2002.631">Cameron A, Rosenfeld J. Nutritional issues and supplements in amyotrophic lateral sclerosis and other neurodegenerative disorders. <span><span class="ref-journal">Curr Opin Clin Nutr Metab Care. </span>2002;<span class="ref-vol">5</span>:631–43.</span> [<a href="/pubmed/12394638" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12394638</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.chia.2018.94">Chia R, Chi&#x000f2; A, Trayner BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. <span><span class="ref-journal">Lancet Neurol. </span>2018;<span class="ref-vol">17</span>:94–102.</span> [<a href="/pmc/articles/PMC5901717/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5901717</span></a>] [<a href="/pubmed/29154141" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29154141</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.chi_.2011.553.e23">Chi&#x000f2; A, Calvo A, Moglia C, Ossala I, Brunetti M, Sbaiz L, Lai SL, Abramzon Y, Traynor BJ, Restagno G. A de novo missense mutation in the FUS gene in a "true" sporadic ALS case. <span><span class="ref-journal">Neurobiol Aging. </span>2011;<span class="ref-vol">32</span>:553.e23–6.</span> [<a href="/pmc/articles/PMC2972379/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2972379</span></a>] [<a href="/pubmed/20598774" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20598774</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.cox.2009.109">Cox PA, Richer R, Metcalf JS, Banack SA, Codd GA, Bradley WG. Cyanobacteria and BMAA exposure from desert dust: a possible link to sporadic ALS among Gulf War veterans. <span><span class="ref-journal">Amyotroph Lateral Scler. </span>2009;<span class="ref-vol">10</span> Suppl 2:109–17.</span> [<a href="/pubmed/19929742" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19929742</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.de_carvalho.2008.497">de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, Mills K, Mitsumoto H, Nodera H, Shefner J, Swash M. Electrodiagnostic criteria for diagnosis of ALS. <span><span class="ref-journal">Clin Neurophysiol. </span>2008;<span class="ref-vol">119</span>:497–503.</span> [<a href="/pubmed/18164242" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18164242</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.farrero.2005.2132">Farrero E, Prats E, Povedano M, Martinez-Matos JA, Manresa F, Escarrabill J. Survival in amyotrophic lateral sclerosis with home mechanical ventilation: the impact of systematic respiratory assessment and bulbar involvement. <span><span class="ref-journal">Chest. </span>2005;<span class="ref-vol">127</span>:2132–8.</span> [<a href="/pubmed/15947331" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15947331</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.goldstein.1998.s114">Goldstein LH, Adamson M, Jeffrey L, Down K, Barby T, Wilson C, Leigh PN. The psychological impact of MND on patients and carers. <span><span class="ref-journal">J Neurol Sci. </span>1998;<span class="ref-vol">160</span> Suppl 1:S114–21.</span> [<a href="/pubmed/9851660" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9851660</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.goutman.2017.1332">Goutman SA. Diagnosis and clinical management of amyotrophic lateral sclerosis and other motor neuron disorders. <span><span class="ref-journal">Continuum. </span>2017;<span class="ref-vol">23</span>:1332–59.</span> [<a href="/pubmed/28968365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28968365</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.haley.2003.750">Haley RW. Excess incidence of ALS in young Gulf War veterans. <span><span class="ref-journal">Neurology. </span>2003;<span class="ref-vol">61</span>:750–6.</span> [<a href="/pubmed/14504316" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14504316</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.hardiman.2017.17071">Hardiman O, Al-Chalabi A, Chi&#x000f2; A, Logroscino G, Robberrecht W, Shaw PJ, Simmons Z, van den Berg LH. Amyotrophic lateral sclerosis. <span><span class="ref-journal">Nat Rev Dis Primers. </span>2017;<span class="ref-vol">3</span>:17071.</span> [<a href="/pubmed/28980624" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28980624</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.horner.2003.742">Horner RD, Kamins KG, Feussner JR, Grambow SC, Hoff-Lindquist J, Harati Y, Mitsumoto H, Pascuzzi R, Spencer PS, Tim R, Howard D, Smith TC, Ryan MA, Coffman CJ, Kasarskis EJ. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. <span><span class="ref-journal">Neurology. </span>2003;<span class="ref-vol">61</span>:742–9.</span> [<a href="/pubmed/14504315" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14504315</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.iacoangeli.2019.115">Iacoangeli A, Al Khleifat A, Jones AR, Sproviero W, Shatunov A, Opie-Martin S, Morrison KE, Shaw PJ, Shaw CE, Fogh I, Dobson RJ, Newhouse SJ, Al-Chalabi A, et al.  C9orf72 intermediate expansions of 24-30 repeats are associated with ALS. <span><span class="ref-journal">Acta Neuropathol Commun. </span>2019;<span class="ref-vol">7</span>:115.</span> [<a href="/pmc/articles/PMC6637621/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6637621</span></a>] [<a href="/pubmed/31315673" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31315673</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.katz.2012.567">Katz JS, Katzberg HD, Woolley SC, Marklund SL, Andersen PM. Combined fulminant frontotemporal dementia and amyotrophic lateral sclerosis associated with an I113T SOD1 mutation. <span><span class="ref-journal">Amyotroph Lateral Scler. </span>2012;<span class="ref-vol">13</span>:567–9.</span> [<a href="/pubmed/22670877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22670877</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.lambrechts.2003.383">Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, Thijs V, Andersson J, van Marion I, Al-Chalabi A, Bornes S, Musson R, Hansen V, Beckman L, Adolfsson R, Pall HS, Prats H, Vermeire S, Rutgeerts P, Katayama S, Awata T, Leigh N, Lang-Lazdunski L, Dewerchin M, Shaw C, Moons L, Vlietinck R, Morrison KE, Robberecht W, Van Broeckhoven C, Collen D, Andersen PM, Carmeliet P. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. <span><span class="ref-journal">Nat Genet. </span>2003;<span class="ref-vol">34</span>:383–94.</span> [<a href="/pubmed/12847526" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12847526</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.li.2004.209">Li YJ, Pericak-Vance MA, Haines JL, Siddique N, McKenna-Yasek D, Hung WY, Sapp P, Allen CI, Chen W, Hosler B, Saunders AM, Dellefave LM, Brown RH, Siddique T. Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis. <span><span class="ref-journal">Neurogenetics. </span>2004;<span class="ref-vol">5</span>:209–13.</span> [<a href="/pubmed/15657798" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15657798</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.lopate.2010.232">Lopate G, Baloh RH, Al-Lozi MT, Miller TM, Fernandes Filho JA, Ni O, Leston A, Florence J, Schierbecker J, Allred P. Familial ALS with extreme phenotypic variability due to the I113T SOD1 mutation. <span><span class="ref-journal">Amyotroph Lateral Scler. </span>2010;<span class="ref-vol">11</span>:232–6.</span> [<a href="/pubmed/20184521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20184521</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.magnus.2002.709">Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. <span><span class="ref-journal">Muscle Nerve. </span>2002;<span class="ref-vol">25</span>:709–14.</span> [<a href="/pubmed/11994965" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11994965</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.miller.1999.1311">Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, Borasio GD, Bradley WG, Bromberg MB, Brooks BR, Kasarskis EJ, Munsat TL, Oppenheimer EA. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. <span><span class="ref-journal">Neurology. </span>1999;<span class="ref-vol">52</span>:1311–23.</span> [<a href="/pubmed/10227612" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10227612</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.montuschi.2015.168">Montuschi A, Iazzolino B, Calvo A, Moglia C, Lopiano L, Restagno G, Brunetti M, Ossola I, Lo Presti A, Cammarosano S, Canosa A, Chi&#x000f2; A. Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2015;<span class="ref-vol">86</span>:168–73.</span> [<a href="/pubmed/24769471" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24769471</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.niven.2015.172">Niven E, Newton J, Foley J, Colville S, Swingler R, Chandran S, Bak TH, Abrahams S. Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): a cognitive tool for motor disorders. <span><span class="ref-journal">Amyotroph Lateral Scler Frontotemporal Degener. </span>2015;<span class="ref-vol">16</span>:172–9.</span> [<a href="/pubmed/25967542" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25967542</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.ohta.2016.4771">Ohta Y, Soucy G, Phaneuf D, Audet JN, Gros-Louis F, Rouleau GA, Blasco H, Corcia P, Andersen PM, Nordin F, Yamashita T, Abe K, Julien JP. Sex-dependent effects of chromogranin B P413L allelic variant as disease modifier in amyotrophic lateral sclerosis. <span><span class="ref-journal">Hum Mol Genet. </span>2016;<span class="ref-vol">25</span>:4771–86.</span> [<a href="/pmc/articles/PMC5418737/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5418737</span></a>] [<a href="/pubmed/28175304" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28175304</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.orrell.2007.cd002829">Orrell RW, Lane RJM, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2007;<span class="ref-vol">24</span>:CD002829.</span> [<a href="/pubmed/17253482" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17253482</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.paillisse.2005.37">Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. <span><span class="ref-journal">Amyotroph Lateral Scler Other Motor Neuron Disord. </span>2005;<span class="ref-vol">6</span>:37–44.</span> [<a href="/pubmed/16036424" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16036424</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.raaphorst.2012.493">Raaphorst J, Beeldman E, De Visser M, De Haan RJ, Schmand B. A systematic review of behavioral changes in motor neuron disease. <span><span class="ref-journal">Amyotroph Lateral Scler. </span>2012;<span class="ref-vol">13</span>:493–501.</span> [<a href="/pubmed/22424127" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22424127</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.rahbari.2016.126">Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR, Hurles ME, et al.  Timing, rates and spectra of human germline mutation. <span><span class="ref-journal">Nat Genet. </span>2016;<span class="ref-vol">48</span>:126–33.</span> [<a href="/pmc/articles/PMC4731925/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4731925</span></a>] [<a href="/pubmed/26656846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26656846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.riviere.1998.526">Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. <span><span class="ref-journal">Arch Neurol. </span>1998;<span class="ref-vol">55</span>:526–8.</span> [<a href="/pubmed/9561981" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9561981</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.ryan.2019a.1001">Ryan M, Heverin M, McLaughlin RL, Hardiman O. Lifetime risk and heritability of amyotrophic lateral sclerosis. <span><span class="ref-journal">JAMA Neurol. </span>2019a;<span class="ref-vol">10</span>:1001.</span> [<a href="/pmc/articles/PMC6646974/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6646974</span></a>] [<a href="/pubmed/31329211" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31329211</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.ryan.2019b.659">Ryan M, Zalvidar Vaillant T, McLaughlin RL, Doherty MA, Rooney J, Heverin M, Gutierrez J, Lara-Fern&#x000e1;ndez GE, Pita Rodriguez M, Hackembruch J, Perna A, Vazquez MC, Musio M, Ketzoian CN, Logroscino G, Hardiman O. Comparison of the clinical and genetic features of amyotrophic lateral sclerosis across Cuban, Uruguayan and Irish clinic-based populations. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2019b;<span class="ref-vol">90</span>:659–65.</span> [<a href="/pubmed/30846540" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30846540</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.sawada.2017.735">Sawada H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. <span><span class="ref-journal">Expert Opin Pharmacother. </span>2017;<span class="ref-vol">18</span>:735–8.</span> [<a href="/pubmed/28406335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28406335</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.saxon.2017.675">Saxon JA, Thompson JC, Jones M, Harris JM, Richardson AM, Langheinrich T, Neary D, Mann DM, Snowden JS. Examining the language and behavioural profile in FTD and ALS-FTD. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2017;<span class="ref-vol">88</span>:675–80.</span> [<a href="/pmc/articles/PMC5537548/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5537548</span></a>] [<a href="/pubmed/28596248" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28596248</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.schreiber.2005.772">Schreiber H, Gaigalat T, Wiedemuth-Catrinescu U, Graf M, Uttner I, Muche R, Ludolph AC. Cognitive function in bulbar- and spinal-onset amyotrophic lateral sclerosis. A longitudinal study in 52 patients. <span><span class="ref-journal">J Neurol. </span>2005;<span class="ref-vol">252</span>:772–81.</span> [<a href="/pubmed/15742104" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15742104</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.strong.2005.8">Strong MJ, Gordon PH. Primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral sclerosis: discrete entities or spectrum? <span><span class="ref-journal">Amyotroph Lateral Scler Other Motor Neuron Disord. </span>2005;<span class="ref-vol">6</span>:8–16.</span> [<a href="/pubmed/16036421" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16036421</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.van_den_berg.2004.226">van den Berg JP, de Groot IJ, Joha BC, van Haelst JM, van Gorcom P, Kalmijn S. Development and implementation of the Dutch protocol for rehabilitative management in amyotrophic lateral sclerosis. <span><span class="ref-journal">Amyotroph Lateral Scler Other Motor Neuron Disord. </span>2004;<span class="ref-vol">5</span>:226–9.</span> [<a href="/pubmed/15799551" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15799551</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.van_rheenen.2016.1043">van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, van der Spek RN, V&#x000f6;sa U, de Jong S, Robinson MR, et al.  Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. <span><span class="ref-journal">Nat Genet. </span>2016;<span class="ref-vol">48</span>:1043–8.</span> [<a href="/pmc/articles/PMC5556360/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5556360</span></a>] [<a href="/pubmed/27455348" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27455348</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.woolley.2010.303">Woolley SC, York MK, Moore DH, Strutt AM, Murphy J, Schulz PE, Katz JS. Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). <span><span class="ref-journal">Amyotroph Lateral Scler. </span>2010;<span class="ref-vol">11</span>:303–11.</span> [<a href="/pubmed/20433413" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20433413</span></a>]</div></li></ul></div><div id="als-overview.Suggested_Reading"><h3>Suggested Reading</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.abe.2017.505">Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, Hamada C, Tanaka M, Akimoto M, Nakamura K, Takahashi F, Kondo K, Yoshino H, et al.  Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. <span><span class="ref-journal">Lancet Neurol. </span>2017;<span class="ref-vol">16</span>:505–12.</span> [<a href="/pubmed/28522181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28522181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.andersen.2017.220">Andersen PM. Is all ALS genetic? <span><span class="ref-journal">Neurology. </span>2017;<span class="ref-vol">89</span>:220–1.</span> [<a href="/pubmed/28642337" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28642337</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.ghasemi.2018">Ghasemi M, Brown RH Jr. Genetics of amyotrophic lateral sclerosis. <span><span class="ref-journal">Cold Spring Harb Perspect Med. </span>2018;<span class="ref-vol">8</span>(5)</span> [<a href="/pmc/articles/PMC5932579/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5932579</span></a>] [<a href="/pubmed/28270533" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28270533</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.ly.2018.648">Ly CV, Miller TM. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. <span><span class="ref-journal">Curr Opin Neurol. </span>2018;<span class="ref-vol">31</span>:648–54.</span> [<a href="/pubmed/30028737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30028737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.oskarsson.2018.1617">Oskarsson B, Gendron TF, Staff N. Amyotrophic lateral sclerosis: an update for 2018. <span><span class="ref-journal">Mayo Clin Proc. </span>2018;<span class="ref-vol">93</span>:1617–28.</span> [<a href="/pubmed/30401437" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30401437</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="als-overview.REF.renaud.2019.103">Renaud L, Picher-Martel V, Codron P, Julien JP. Key role of UBQLN2 in pathogenesis of amyotrophic lateral sclerosis and frontotemporal dementia. <span><span class="ref-journal">Acta Neuropathol Commun. </span>2019;<span class="ref-vol">7</span>:103.</span> [<a href="/pmc/articles/PMC6889556/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6889556</span></a>] [<a href="/pubmed/31319884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31319884</span></a>]</div></li></ul></div></div><div id="als-overview.Chapter_Notes"><h2 id="_als-overview_Chapter_Notes_">Chapter Notes</h2><div id="als-overview.Author_History"><h3>Author History</h3><p>Lisa Dellefave, MS, CGC; University of Chicago (2000-2009)<br />Sandra Donkervoort, MS, CGC; Northwestern University Feinberg School of Medicine (2009-2012)<br />Mara Gaudette, MS; Northwestern University Medical School (2000-2006)<br />Lisa Kinsley, MS, CGC; Northwestern University Feinberg School of Medicine (2012-2019)<br />Nailah Siddique, RN, MSN (2019-present)<br />Teepu Siddique, MD (2000-present)</p></div><div id="als-overview.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>3 October 2019 (bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>12 February 2015 (cd) Revision: ALS/FTD nomenclature</div></li><li class="half_rhythm"><div>31 May 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>28 July 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 November 2007 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for <i>SETX</i> mutations available clinically</div></li><li class="half_rhythm"><div>6 August 2007 (cd) Revision: testing available clinically for <i>SETX</i>-related amyotrophic lateral sclerosis</div></li><li class="half_rhythm"><div>23 June 2006 (ca) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 February 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 November 2001 (mg) Author revisions</div></li><li class="half_rhythm"><div>23 March 2001 (tk) Overview posted live</div></li><li class="half_rhythm"><div>August 2000 (mg) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1450</span><span class="label">PMID: <a href="/pubmed/20301623" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301623</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/amish-mcph/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/acpp/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1450&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1450/?report=reader">PubReader</a></li><li><a href="/books/NBK1450/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1450" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1450" style="display:none" title="Cite this Page"><div class="bk_tt">Siddique N, Siddique T. Amyotrophic Lateral Sclerosis Overview. 2001 Mar 23 [Updated 2019 Oct 3]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1450/pdf/Bookshelf_NBK1450.pdf">PDF version of this page</a> (529K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#als-overview.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#als-overview._escape__1_Clinical_Charact" ref="log$=inpage&amp;link_id=inpage">1. Clinical Characteristics of ALS</a></li><li><a href="#als-overview._escape__2_Genetic_Causes_o" ref="log$=inpage&amp;link_id=inpage">2. Genetic Causes of ALS</a></li><li><a href="#als-overview._escape__3_Evaluation_Strat" ref="log$=inpage&amp;link_id=inpage">3. Evaluation Strategies to Identify the Genetic Cause of ALS in a Proband</a></li><li><a href="#als-overview._escape__4_Genetic_Counseli" ref="log$=inpage&amp;link_id=inpage">4. Genetic Counseling</a></li><li><a href="#als-overview.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#als-overview._escape__5_Management_of_AL" ref="log$=inpage&amp;link_id=inpage">5. Management of ALS</a></li><li><a href="#als-overview.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#als-overview.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3178[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HNRNPA1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=29110[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TBK1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6647[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SOD1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=10280[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SIGMAR1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4744[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">NEFH</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=400916[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CHCHD10</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=29978[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">UBQLN2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=25978[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CHMP2B</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=9782[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MATR3</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2066[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ERBB4</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7415[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">VCP</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=10133[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">OPTN</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4750[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">NEK1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=283[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ANG</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8878[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SQSTM1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=80208[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SPG11</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5216[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PFN1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=9217[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">VAPB</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=23435[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TARDBP</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2521[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FUS</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=9896[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FIG4</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=203228[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">C9orf72</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=57679[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ALS2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=23064[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SETX</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1639[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">DCTN1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5630[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PRPH</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7277[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TUBA4A</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1479152" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1479152" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26804609" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Mutational analysis of TBK1 in Taiwanese patients with amyotrophic lateral sclerosis.</a><span class="source">[Neurobiol Aging. 2016]</span><div class="brieflinkpop offscreen_noflow">Mutational analysis of TBK1 in Taiwanese patients with amyotrophic lateral sclerosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tsai PC, Liu YC, Lin KP, Liu YT, Liao YC, Hsiao CT, Soong BW, Yip PK, Lee YC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Neurobiol Aging. 2016 Apr; 40:191.e11-191.e16. Epub 2016 Jan 5.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25109764" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Identify mutation in amyotrophic lateral sclerosis cases using HaloPlex target enrichment system.</a><span class="source">[Neurobiol Aging. 2014]</span><div class="brieflinkpop offscreen_noflow">Identify mutation in amyotrophic lateral sclerosis cases using HaloPlex target enrichment system.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Liu ZJ, Li HF, Tan GH, Tao QQ, Ni W, Cheng XW, Xiong ZQ, Wu ZY. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Neurobiol Aging. 2014 Dec; 35(12):2881.e11-2881.e15. Epub 2014 Jul 11.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28889094" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the &lt;i&gt;C9orf72&lt;/i&gt; expansion mutation.</a><span class="source">[J Neurol Neurosurg Psychiatry....]</span><div class="brieflinkpop offscreen_noflow">Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the &lt;i&gt;C9orf72&lt;/i&gt; expansion mutation.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dols-Icardo O, García-Redondo A, Rojas-García R, Borrego-Hernández D, Illán-Gala I, Muñoz-Blanco JL, Rábano A, Cervera-Carles L, Juárez-Rufián A, Spataro N, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Neurol Neurosurg Psychiatry. 2018 Feb; 89(2):162-168. Epub 2017 Sep 9.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29626651" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Autophagy as a common pathway in amyotrophic lateral sclerosis.</a><span class="source">[Neurosci Lett. 2019]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Autophagy as a common pathway in amyotrophic lateral sclerosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nguyen DKH, Thombre R, Wang J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Neurosci Lett. 2019 Apr 1; 697:34-48. Epub 2018 Apr 4.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24488689" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research.</a><span class="source">[Muscle Nerve. 2014]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Su XW, Broach JR, Connor JR, Gerhard GS, Simmons Z. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Muscle Nerve. 2014 Jun; 49(6):786-803. Epub 2014 Apr 8.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301623" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301623" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04160c39a66ee2ba1422b2">Amyotrophic Lateral Sclerosis Overview - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Amyotrophic Lateral Sclerosis Overview - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:08:12-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE89B1E7E0403A510000000008F503EF&amp;ncbi_session=CE89B1E7E04160B1_2293SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1450%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1450&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1450/&amp;ncbi_pagename=Amyotrophic Lateral Sclerosis Overview - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE89B1E7E04160B1_2293SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>